INDEX

Note: Page numbers in *italics* indicate figures. Page numbers followed by a “t” indicate tables.

ACAM2000, 124t, 479, 482t, 483-484. See also Smallpox.
Acetaminophen, 145
ACIP. See Advisory Committee on Immunization Practices.
ActHIB (Hib-T), 121t, 173t, 191, 344, 345, 346t-347t
Active Bacterial Core surveillance (ABCs), 76
Acute disseminated encephalomyelitis (ADEM), 269-270
Ad-hoc committees and task forces, 81
Adacel (Tdap), 65t, 123t, 205, 330t-332t. See also Tdap vaccines.
Adaptive immune system, 19, 24, 25, 27
Additives in vaccines, 259, 537
Adenovirus, 303-308
clinical features, 303-304
epidemiology and transmission, 304
immunization program, 304
pathogen, 303
vaccine, 16, 304, 305t
contraindications/precautions, 306-307
immunogenicity/efficacy, 306
recommendations, 305t, 307
safety, 306-307
storage, 120t
Adjuvants, 26, 27, 28t-29t, 258, 537. See also specific vaccines.
action mechanisms of, 28t-29t
alum/aluminum, 26, 28t, 258
antigen sparing and, 26
AS01, 29t, 258
AS03, 28t, 401
AS04, 28t, 258
CpG 1018, 29t, 258, 364t
MF59, 29t, 258
thimerosal, 254, 264-266
Administration of vaccines, continued
grace period, 111-112, 154, 155, 163
interchangeability of vaccines from different manufacturers, 164
intervals for vaccinations, 153-167, 156t-162t
doses in a series, 163-164
doses of same vaccine, 155-163
inactivated vaccines, 154-155
lapse in series and, 163-164
between live vaccines and antibody-containing blood products, 165-166, 168t-170t
live vaccines not given at the same time, 154
simultaneous administration, 64t, 153-154
minimum age and intervals, 154-167, 156t-162t, 290
multiple vaccines
simultaneous administration of, 64t, 94, 137, 153-154
exceptions, 153
no maximum number of vaccinations in single day, 177
using different sites for, 137, 153
needle type and length, 142, 143t
for persons who have had the disease, 165, 181t
prefilled syringes, 119, 177
routes of administration, 137-142
errors in, 167
intradermal, 141, 142
intramuscular, 137-142, 141
intranasal, 142, 144
jet injectors, 142
needle type and length, 142, 143t
oral, 142, 144
subcutaneous, 141, 142
schedules for. See Schedules.
ten simple rules, 153-167
waiting (observation) time after, 145
"when in doubt, vaccinate," 165
Adolescent immunization, 95, 134, 287-288
barriers to immunization, 92-93, 96t
coverage goals, 91
coverage rates, 73, 74
Denver Health example, 134, 135t
DTap series vs Tdap, 326-328, 337-338
hepatitis B vaccine, 290, 369-370
HPV vaccine, 290, 294, 298, 380, 383t, 385-386
immunization platforms
early adolescent, 287, 302t
late adolescent, 287-288, 302t
improving delivery, 134, 135t
N meningitidis, 95, 290, 432, 433, 434, 442-443
schedules, 442-443
catch-up, 294-295
routine (for healthy persons), 290-291
Adolescent immunization, continued
  routine young adult, 298-299
  special immunizations, 296t-297t
  standards for, 92-95
  syncope and, 145
  tactics for vaccine delivery, 135t
Adoptees, international, 220-221, 350
Adult immunization, 287, 298-300. See also Older adults.
  coverage goals, 91-92
  improving rates of, 134, 136t-137t
  at pediatric office visit, 130, 131t
  schedules. See also specific vaccines.
    by age group, 298-299
    by medical indication, 300-301
    standards for, 95-97, 98t-99t
  young adult immunization platform, 302t
Adventitious agents, 273
Adverse events, 76-81. See also Vaccine Safety Net; specific vaccines.
  causality and, 77, 77t, 97, 236
  clinical trials and numbers of subjects to detect, 56-58, 57t
  clustered anxiety-related adverse events, 278
  contraindications and precautions, 177-178
    screening for, 134, 138t-140t, 240t-241t
  definition of, 77, 77t
  effect on recommendations, 238t
  genetics and, 43-46
  mandatory reporting requirements, 77, 94, 101
  Reportable Events, 97-101, 106t-109t
  Reporting System (VAERS), 77-79, 101
  Advisory Committee on Immunization Practices (ACIP), vi, 63-70, 66
    recommendations, vii-viii, 63-70, 64t-65t, 539
    Category A or B, 70, 72t
    GRADE approach, 67-70, 71t
    for pregnancy and breast-feeding, 211
    on simultaneous administration of vaccines, 64t, 154
    working groups of, 67
  Advocacy organizations, 555t-556t
  Affinity maturation, 25, 26
  Affordable Care Act (ACA), 82
  AFIX, 134
  Afluria (IIV, influenza), 144, 398t
Age. See also Schedules for immunization.
  definition of, vii
  grace period and, 111-112, 154, 155, 163
  minimum ages for vaccines, 19, 154-167, 156t-162t, 290
  Agencies and committees, 54, 66
  AIDS. See also HIV.
    polio vaccine not the cause of, 271
    response to vaccines and, 185
  Alcoholism, vaccinations recommended, 300-301
  Allergies, 177, 260-262. See also specific vaccines.
    allergic reactions to vaccine components, 177, 259, 333, 336.
    See also Contraindications and precautions.
    to eggs, 259, 523
    hygiene hypothesis and, 260
  Allied Vaccine Group, 555t
  Alternative schedules, 248, 259-260
  Alum/aluminum salts, 26, 28t, 258
  American Academy of Family Physicians (AAFP), vii, 287, 539, 554t
  American Academy of Pediatrics (AAP), vii, 133, 554t
  recommendations, 70-71, 287, 539
  Red Book, 71
  American College Health Association (ACHA), 554t
  American College of Nurse-Midwives, 287
  American College of Obstetricians and Gynecologists (ACOG), 287, 554t
  American College of Physicians (ACP), 95, 287, 554t
  American Immunization Registry Association, 555t
  American Medical Association (AMA), 555t
  American Nurses Association (ANA), 555t
  American Pharmacists Association (APA), 555t
  American Public Health Association (APHA), 555t
  Anamnestic response, 22, 26, 31
  Anaphylaxis, 106t-107t, 146, 369
    signs and symptoms of, 146
  Animal workers, vaccination of, 111, 228t, 460t
  Anogenital warts, 378, 379, 384, 568t
  Anthrax, 309-316
    antibiotic therapy, 310, 311
    bioterrorism potential, 309-310
    clinical features, 309
    epidemiology and transmission, 309-310
    immunization program, 310
    monoclonal antibodies, 311
    pathogen, 309, 568t
    vaccine, 12t, 311, 312t
      characteristics and specifics of, 312t
      contraindications/precautions, 313
      immunogenicity/efficacy, 311
      recommendations/schedule, 313
      bioterrorism recommendations, 310
        civilian use, 310, 314t-315t
        military use, 311, 313
      postexposure prophylaxis, 311, 312t
      pre-exposure vaccination, 310-311, 312t
      safety, 311-312
      storage, 120t
Antibodies, 19-21, 27. See also Immune globulin; Immune response.
  action mechanisms and sites, 19-21, 20
  antibody-dependent cell-mediated cytotoxicity, 19-21, 35
  broadly neutralizing, 21
  engineered, 19
  germline, 23
  high-affinity, 25, 27
  passive immunization with, 11, 18-19
  persistence of, 27-31
  prevention of viral infection, 21
  production of, 21-32, 22
  adjuvants and, 26, 27, 28t-29t, 258
  extrafollicular reaction, 21-23, 22
  germinal center reaction, 22, 23-32
  priming and boosting, 26-27, 30, 31
  quantification/measurement of, 40
  specificity of, 19, 27, 27
  testing for, 167-171
  rubella antibodies, 210
  time course of responses, 26-27, 30
  to toxins, 40
Antibody-containing products, intervals for live vaccines and,
  165-166, 168t-170t
Antigen-presenting cells (APCs), 22, 24-25, 31-32, 34
Antigens, 11, 20, 27. See also Antibodies.
  adjuvants and, 26, 27
  antigen sparing, 26
  antigenic competition, 537
  antigenic drift, 391
  antigenic shift, 391
  cross-reactive, 27
  immunogenicity, 31-32
  number of
    in combination vaccines, 539
    in routine vaccines, 256, 257t
    polysaccharide, 17, 21-23, 22, 31
  reassortment, 16, 391, 401
  T-cell independent, 23
Antitoxins, 19
Antivaccinationism, 248-249, 250t-252t
Anxiety, dealing with, 142-145
APCs. See Antigen-presenting cells.
Apoptosis, 32
Apremilast, 201
AS01, 29t, 258
AS03, 28t, 401
AS04, 28t, 258
Aspirin, Reye syndrome and, 138t, 228t, 406, 408, 513
Asplenia, 194, 199-200, 296t, 300-301, 345, 348
Association for Prevention Teaching and Research, 555t
Association of State and Territorial Health Officials, 555t
Asthma, 200, 261, 407
Attenuation of vaccines, 11-16, 12t
  altered site of infection, 16
  engineered, 16
  heterologous host, 16
  reassortment, 16
  serial passage, 11-16
Autism, 263-266
  MMR vaccine and, 263-264
  Omnibus Autism Proceedings, 265-266
  thimerosol and, 264-266
Autoimmunity, 25, 260-262
  autoimmune diseases, 200, 260-262
B cells, 21-23, 25, 27
  activation of, 21, 25
    bystander activation, 30
  B-cell deficiencies, 191-198
  B-cell receptor, 21, 22, 31
  clonal expansion/proliferation of, 21, 25
  differentiation of, 27-30
  memory B-cells, 22, 25-26, 27, 31
  Bacille Calmette-Guérin (BCG), 16
  *Bacillus anthracis*, 309, 568t. See also Anthrax.
  Bacteria. See also specific bacteria.
    Active Bacterial Core surveillance system, 76
    antibody effects on, 19-21, 20
    attenuation of, 16
    Tc-cells and, 32-35
    vaccines against, 35
BARDAS (Biomedical Advanced Research and Development Authority), 62
Barrier defect, 188-189
BCG (Bacille Calmette-Guérin), 16
Behavioral Risk Factor Surveillance System (BRFSS), 73-75, 557t
Bell’s Palsy, 276, 442
Bexsero. See MenB-4C.
Bill & Melinda Gates Foundation, 555t
Biologics License Application (BLA), 54, 58-59
Biomedical Advanced Research and Development Authority
  (BARDA), 62
Bioterrorism
  anthrax and, 309-310
  smallpox and, 46-47, 478
BioThrax, 120t, 312t. See also Anthrax.
Bird flu (influenza A; H5N1). See also Influenza.
Birth defects, 177, 205, 277-278
  percentage of all babies born with, 210
  varicella and, 508
Birth vaccinations, 211, 290, 362, 368, 369
BLA (Biologics License Application), 54, 58-59
Bleeding diathesis, 228t
Blood transfusion, interval for live vaccines and, 169t
Bloodborne Pathogens Standard, 105-111
Bone marrow (HSCT) transplantation, 204, 206t-209t
Books on vaccines, 558t
Booster vaccination, 26-27, 30, 31
Boostrix (Tdap), 65t, 123t, 205, 329, 330t-332t, 338.
See also Tdap vaccines.
Bordetella pertussis, 17, 323, 325, 568t. See also Pertussis.
Botulism, immune globulin (BabyBig), 169t
Brain damage, pertussis vaccine concerns, 266-267
“Breakthrough therapy” category, 59
Breast-feeding, 180t, 211, 475, 486t, 524. See also Pregnancy.
BRFSS (Behavioral Risk Factor Surveillance System), 73-75, 557t
Brighton Collaboration, 80, 555t
Butte County, California (hepatitis A in), 43, 351

Cancer, 377-378, 379, 379
   anal, 379, 379
   cervical, 377-378, 379
   chemotherapy for, 203-204, 348
   hepatocellular, 362
   HPV and, 255-256, 377-379, 379
   oral, 378, 379
   penile, 378, 379
   polio vaccine and, 270-271
   vaginal, 378, 379
Catch-up immunization schedules
   children, age 4 months-6 years, 292-293
   children, age 7-18 years, 294-295
Causal relationships, 77t, 99, 233-236, 236
CBER, 53-55, 54, 66
CD4, 22, 24, 32, 34, 184
CD8, 32, 34, 184
CD40, 22, 198
CDC. See Centers for Disease Control and Prevention.
Celiac disease, 262
Centers for Biologics Evaluation and Research (CBER), 53-55, 54, 66
 Centers for Disease Control and Prevention (CDC), 62, 66, 554t
   disease surveillance, 76
   vaccine stockpiles, 87, 401
Cerebrospinal fluid. See CSF leaks.
Cervarix (HPV2), 380. See also Human papillomavirus.
Cervical cancer, 256, 377-378, 379
   CIN grades, 377-378
   Chemotherapy, 203-204, 348
   Chickenpox, 35, 164, 255, 480t, 507, 508. See also Varicella.
   acyclovir used to prevent, 516
   differentiating from smallpox, 480t-481t
   as nearly eliminated in the US, 511
   potentially caused by lesions from herpes zoster, 528
   questionable history of, 165
Children. See also Adolescent immunization; Infants.
   aspirin therapy and, 408
   Childhood Immunization Support Program, 71
   co-cooing strategy, 130, 326-328
   coding for routine visit, 147, 148t-149t
   costs of immunization, 82t
   coverage goals, 91
   coverage rates, 73, 74
   HIV-infected, 187-191
   immunization schedules, 290-295
   catch-up, age 4 months-6 years, 292-293
   catch-up, age 7-18 years, 294-295
   exemptions from, 112-113
   financing for, 82-83
   grace period, 111-112, 154, 155, 163
   routine immunizations, age 0-18 years, 290-291
   special immunizations, 296t-297t
   immunization standards, 92-95
   impact of routine childhood vaccination, 52t
   National Childhood Vaccine Injury Act, 77, 81, 97-101
   pain relief for, 142-145
   participation in Immunization Information Systems (IISs), 133
   school-aged immunization platform, 302t
   school-located vaccination (SLV), 131-132
   specific vaccines
      hepatitis A, 290, 351
      hepatitis B, 290, 362-363, 369-370
      HPV, 380, 385-386
      influenza, 394, 396, 407-408
      MMR, 428
      MMRV, 539
      pneumonia, 495-496
      polio, 449
      Tdap and DTaP, 290, 327, 337
      varicella, 509, 514
Vaccines for Children (VFC) Program, 63, 82-83, 84t-85t
Children’s Health Insurance Program (CHIP), 86
Children’s Hospital of Philadelphia Vaccine Education Center, 555t
Children’s Vaccine Program at PATH, 555t
Cholera, 317-322
   clinical features, 317
   epidemiology and transmission, 317-318
   immunization program, 318
   pathogen, 317, 568t
Cholera, continued
vaccine, 319, 320t-321t
contraindications/precautions, 319-321
immunogenicity/efficacy, 319
recommendations, 320t, 321
for travel, 227, 321
safety, 319-321
storage, 123t
trade name (Vaxchora), 319, 320t
Cholera toxin, 317, 318
Chronic fatigue, 278
Chronic granulomatous disease (CGD), 184
Classification of vaccines, 12t-13t
Clinical Immunization Safety Assessment (CISA) Network, 79-80, 555t
Clinical trials, 55-58, 56
for combination vaccines, 537-538
human subjects, protection of, 55
numbers of subjects required, 56-58, 56, 57t
phase 1, 2, 3, and 4 trials, 55-58, 56
Clonal expansion/proliferation, 21, 25
Clostridium tetani, 323, 325, 568t. See also Tetanus.
Clotting-factor disorders, 297, 356
CoCASA, 134, 557t
Cochlear implants, 186, 406
Cocooning strategy, 130, 326-328
Coding and billing, 146-150, 148t-149t
CPT codes, 146-147, 148t-149t
ICD codes, 147, 148t-149t
NDCs (National Drug Codes), 147
reimbursement according to antigens delivered, 538
routine infant office visit (example), 147, 148t-149t
College students, vaccination of, 228t, 433, 434, 443
Combination vaccines, 537-552, 569t
adjuvants and excipients in, 537, 543t, 549t
advantages of, 537-538
improved coverage and timeliness, 538
reduction in number of shots, 153, 537, 538
clinical trials for, 537-538
contraindications/precautions, 539
immunogenicity/efficacy, 538
noninferiority standard, 538
overimmunization, concern about, 539
preference for, 539
production and usage issues, 437
recommendations, 539
reimbursement for, 538
safety, 538-539
specific vaccines, 540t-551t, 569t
DTaP-based, 120t, 538-539, 540t-546t
Combination vaccines, continued
other than DTaP-based, 548t-551t
terminology and nomenclature, vii, 568t-569t
Common variable immunodeficiency (CVID), 184-185, 191
Communicating about vaccines, 233-244. See also Concerns about vaccines, addressing:
antivaccinationism, 248-249, 250t-252t
public harm from, 249-254
biases, 233-236
causality, ideas about, 233-236, 236
HPV vaccine for adolescents, 386-388, 387t
human nature and perceptions, 233-237, 236
pitfalls to avoid, 245t
questionnaires, 240t-241t, 243
risks vs benefits, 233-244
sources of information, 240-241, 242
specific concerns, 254-279
strategies for, 237-244, 240t-241t, 387t
vaccine confidence, teaching, 244
vaccine refusal, 246-248, 246
Community education, 134
Community immunity. See Herd immunity.
Community service providers, 229t
Compensation. See Vaccine Injury Compensation Program.
Complement deficiencies, 184, 194-195, 199, 300-301, 345
Complement-mediated lysis, 19, 20
Component vaccines, 12t, 17-18
Comprehensive Clinic Assessment Software Application (CoCASA), 134, 557t
Concerns about vaccines, addressing, 233-285
action vs inaction, 233
antivaccinationism, 248-249, 250t-252t
emotional appeals and tropes, 249, 250t, 251t
flawed thinking, 252t
public harm from, 249-254
causal relationships, 233-236, 236
communicating risks and benefits, 233-244
biases, 233-236
communication strategies, 237-244, 240t-241t, 387t
human nature and, 233-237, 236
language and meaning, 245t
questionnaires, 240t-241t, 243
risk vs benefit, balancing, 237, 238t
safety, meaning of, 237
sources of information, 240-241, 242
costs of public concern, 249-254
risks vs benefits, balancing, 237, 238t
sources of information on vaccines, 240-241, 242
specific concerns, 254-279
additives, 259
Concerns about vaccines, addressing, continued
adjuvants, 258
adventitious agents, 273
AIDS, polio vaccine and, 271
allergies and autoimmune diseases, 260-262
alternative schedules, 259-260
autism, 263-266
Bell's Palsy, 276
brain damage, pertussis vaccine and, 266-267
cancer, SV40 contamination and, 270-271
chronic fatigue, 278
clustered anxiety-related adverse events, 278
demyelinating diseases, 268-270
febrile seizures, 274
fetal tissue, 263
Guillain-Barré syndrome, 267-268
immune overload, 256-258
immune thrombocytopenia, 237, 275
Kawasaki disease, 272-273
mad cow disease, 270
miscarriage and birth defects, 277-278
multiple sclerosis, 268-269
narcolepsy, 276-277
natural vs vaccine-induced immunity, 255-256
necessity of vaccines, 254-255
nonspecific negative effects, 262-263
polio vaccine, AIDS pandemic and, 271
primary ovarian insufficiency (POI), 278-279
rotavirus vaccines and intussusception, 237, 274-275
SIDS, 271-272
thimerosal, 264-266
vaccine acceptance, hesitancy, and confidence, 233, 234t, 244
vaccine refusal, 246-248
Confirmation bias, 233-236
Conjugate (protein-polysaccharide) vaccines, 31-32, 33t
Contaminants, 177, 270-271, 273, 537. See also specific vaccines.
Contraindications and precautions, 177-178. See also specific vaccines.
Costs, continued
of routine childhood vaccinations, 52t, 82t
savings due to immunization, 52t
of vaccine administration, 147
of vaccine development, 53
of vaccine-preventable diseases, 95
vaccine purchasing group, 147
of vaccines, 82t, 147, 150. See also specific vaccines.
variation in, 150
Coverage, 73-75, 557t
defined, 73
goals, 91-92
for adolescents, 91
for adults, 91-92
for children, 91
improved, with combination vaccines, 538
rates for adolescents, 73, 74
rates for children, 73, 74, 75
school surveys, 75
in special populations, 186-187, 192t-193t
Cows, mad cow disease, 270
CpG 1018, 29t, 258, 364t
CPT codes, 146-147, 148t-149t
Cytokines, 22, 24, 34
Cytotoxic T cells (Tc cells), 25, 32-36, 34
activation of, 32, 34
cross-protection and, 36
implications for vaccination, 32-35
Cytotoxicity, antibody-dependent cell-mediated, 19-21
Daptacel (DTaP), 120t, 330t-332t. See also DTaP vaccines.
Day care centers
immunization mandates for, 111-113
vaccination of workers, 229t, 356
Deaths
from influenza, 392, 393-394, 394
from measles, 418
from pneumonia, 216, 490
from smallpox, 46, 477
sudden infant death syndrome (SIDS), 271-272
from vaccine-preventable diseases, 95, 392, 393-394, 394
Defense Medical Surveillance System (DMSS), 80
Deferral of doses, 87
Delayed-type hypersensitivity, 177
Delivery of vaccines, 128-134

documentation of vaccinations received, 128
immunization coalitions, 134
Immunization Information Systems (IISs), 132-133
medical home and immunization neighborhood, 129-130
missed opportunities, 129, 178
monitoring, 73-75
other strategies for improving, 134
   AFIX, 134
   community education, 134
   4 Pillars Program, 134, 136t-137t
reminder, recall, and tracking systems, 128-129
school-located vaccination, 131-132
standing orders, 132
Demyelinating diseases, 267-270
Dendritic cells, 23-24
Denver Health, adolescent immunization strategies, 134, 135t
Department of Defense (DOD), 66
   Defense Medical Surveillance System, 80
Development of vaccines. See Vaccine development and licensure.
Developmentally disabled, staff of institutions, 229t, 370, 371
Diabetes, 261-262
   vaccination recommendations, 186, 297t, 300-301, 370
DiGeorge syndrome, 178, 184, 198
Diphtheria, tetanus, and pertussis, 323-341. See also individual entries for Diphtheria, Tetanus, Pertussis.
clinical features, 324-325
epidemiology and transmission, 325-326
immunization programs, 326-328
pathogens, 323-324, 568t
vaccines, 328, 330t-332t, 334t-335t
administration errors and remedies, 172t-173t
characteristics and specifics of, 330t-332t, 334t-335t, 568t
combination vaccines, 540t-546t
contraindications/precautions, 333-337
DTaP-based, 330t-332t, 540t-546t
immunogenicity/efficacy, 328-333
recommendations, 326-328, 327, 337-338
adolescents, 326
adult. See Tdap vaccines.
   children/infants. See DTaP vaccines.
safety, 333-337
trade names, 330t
   Adacel (Tdap), 330t-332t
   Boostrix (Tdap), 330t-332t
   Daptacel (DTaP), 330t-332t
   Infanrix (DTaP), 330t-332t
   Tenivac (Td), 334t-335t
   waning immunity, 329
Diphtheria and Tetanus Toxoids Adsorbed (DT), 120t, 334t-335t, 337
correction, 38t
drug users, injecting, 228t, 297t, 355, 370, 371
DT (diphtheria, tetanus toxoids), 120t, 334t-335t, 337
contraindications/precautions, 336-337
DTaP vaccines, 330t-332t, 540t-546t. See also Diphtheria, tetanus, and pertussis.
   administration errors and remedies, 172t-173t
   combination vaccines, 120t, 538-539, 540t-546t
   Kinrix (DTaP-IPV), 120t, 540t-546t
   Pediari (DTaP-HepB-IPV), 64t, 540t-546t
   Pentacel (DTaP-IPV/Hib-T), 120t, 449, 540t-546t
   Quadracel (DTaP-IPV), 120t, 540t-546t
   Vaxelis (DTaP-HepB-IPV-Hib-OMP), 120t, 540t-546t
Diphtheria, tetanus, and pertussis, continued
   Infanrix (DTaP), 330t-332t
   waning immunity, 329
Diphtheria, 323-341. See also Pertussis; Tetanus.
clinical features, 324
epidemiology and transmission, 325
correlates of protection, 38t
immunization program, 326
pathogen, 323, 325, 568t
resurgence of, 326
vaccines, 12t, 328, 330t-332t, 334t-335t, 568t. See also DT; DTaP vaccines; Tdap vaccines.
   combination vaccines, 538-539, 540t-546t
   contraindications/precautions, 333-337
   DTwP replacement by DTaP, 255, 326, 537
   immunogenicity/efficacy, 328-333
   recommendations, 326-328, 327, 337-338
   safety, 333-337
   schedule, 331t, 334t, 337-338
   storage, 120t
   trade names, 330t, 334t
   Adacel (Tdap), 330t-332t
   Boostrix (Tdap), 330t-332t
   Daptacel (DTaP), 330t-332t
   Diphtheria and Tetanus Toxoids Adsorbed (DT), 334t-335t
   Infanrix (DTaP), 330t-332t
   Tenivac (Td), 334t-335t
   waning immunity, 329
Disease-modifying antirheumatic drugs (DMARDs), 200-201
Documentation of vaccinations received, 128
Dosing
   administration errors, and remedies, 167, 171t-176t
   correction for errors in, 172t
   deferral of doses, 87
   expired or invalid dose, 118, 155, 167, 172t
   partial or fractional doses, 172t, 177
Drug users, injecting, 228t, 297t, 355, 370, 371
DT (diphtheria, tetanus toxoids), 120t, 334t-335t, 337
contraindications/precautions, 336-337
DTaP vaccines, 330t-332t, 540t-546t. See also Diphtheria, tetanus, and pertussis.
   administration errors and remedies, 172t-173t
   combination vaccines, 120t, 538-539, 540t-546t
   Kinrix (DTaP-IPV), 120t, 540t-546t
   Pediari (DTaP-HepB-IPV), 64t, 540t-546t
   Pentacel (DTaP-IPV/Hib-T), 120t, 449, 540t-546t
   Quadracel (DTaP-IPV), 120t, 540t-546t
   Vaxelis (DTaP-HepB-IPV-Hib-OMP), 120t, 540t-546t
DTaP vaccines, continued
contraindications/precautions, 333-336
DTwP replaced by, 255, 326, 537
immunogenicity/efficacy, waning immunity and, 329
minimum ages and intervals, 155-162, 156t, 290
recommendations, 327, 331t, 337
preference for same product for entire series, 164
wound management, 340t-341t
safety, 333-336
encephalopathy and, 177, 269, 333
schedule, 331t, 337
children, age 0-18 years, 290
catch-up, children age 4 months-6 years, 292
storage, 120t
trade names (Daptacel, Infanrix), 330t-332t
vs Tdap, 164
waning immunity and, 329
DTwP vaccine, 255, 262, 266, 326, 547

Eculizumab (Solaris), 199
Education on immunizations, 93
Effectiveness of vaccines, vs efficacy, 36, 58
Efficacy. See also specific vaccines.
correlates of protection, 36-40, 38t-39t
effectiveness vs, 36, 58
Eggs
allergy to, 259, 523
influenza vaccines, “egg-free,” 398t, 401
serial passage in, 11
Elimination of disease, 46-48, 49t
Emergencies, 127t, 145-146
anaphylaxis, 146
power and weather, vaccine storage during, 127t
PREP Act, 101, 484
syncope, 106t-109t, 145-146
Emergency preparedness, 62, 101, 145-146
for anaphylactic reactions, 146
Public Readiness and Emergency Preparedness (PREP) Act, 101, 484
vaccine stockpiles for, 62, 87, 401, 483
vaccine storage and handling, 127t
EMLA cream, 145
Encephalitis
Japanese encephalitis, 411-416
measles and, 418
postvaccination (vaccine-associated neurotropic disease), 523, 525
smallpox and, 477
varicella and, 508
yellow fever vaccine and, 523

Encephalopathy, 106t, 269-270
acute, as vaccine contraindication, 177
DTaP/Tdap vaccine and, 177, 266, 333, 336
Engerix-B (Hep-B vaccine), 121t, 363, 364t-367t, 370
Engineered agent vaccines, 12t, 17-18
Engineered antibodies, 19
Engineered subunits, 12t, 17-18
Epidemiology and Prevention of Vaccine-Preventable Diseases. See "Pink Book".
Epitopes, 19, 27
carrier-induced epitopic suppression, 537
epitope spread, 26
Eradication of disease, 46-47, 49t
Errors in administration of vaccines, 167, 171t
corrections for, 172t-176t
ESRD, vaccinations in, 300-301, 370
Excipients and contaminants, 177, 259, 537. See also specific vaccines.
Exemptions from immunization requirements, 112-113
Extinction of disease, 46-47
Extrafollicular reaction, 21-23, 22

Families Fighting Flu, 555t
FDA. See Food and Drug Administration (FDA).
Fear of vaccines, harm from, 249-254
Febrile multiple organ-system failure, 521-523
Febrile seizures, 145, 154, 274, 411, 420, 424, 538-539
Fetal tissue in vaccine manufacture, 263
Filamentous hemagglutinin (FHA), 17, 323, 330t
Fimbriae (FIM), 17, 323, 330t
Financing of immunization, 81-86
public sector funds, 82-86
Section 317 funds, 83-86
state and local funds, 86
universal purchase states, 86
Vaccines for Children (VFC) Program, 82-83, 84t-85t
Flu. See Influenza.
Fluad, 398t, 401
Fluarix (IV, influenza), 173t, 398t
Flublok (riIV) (“egg-free” influenza vaccine), 398t, 401
Flucelvax (ccIV), 398t, 401
Flulaval, 173t, 398t
Flumist (LAIV, live influenza), 121t, 144, 398t
Fluzone (IV, influenza), 399t
Fluzone High-Dose (hdIV, influenza), 215, 397, 399t, 403
Food and Drug Administration (FDA), 53, 54, 66, 554t
vaccine development and licensure, 53-55, 54, 78
Food handlers, vaccination of, 228t, 356
Foresters, vaccination of, 228t
Four Pillars Program, 134, 136t-137t
Freezer, storage of vaccines in, 119-126, 123t-124t

Gardasil (HPV4), 380, 381, 384-385
Gardasil 9 (HPV9), 121t, 380-388, 382t-383t. See also Human papillomavirus.
Gastroenteritis. See Rotavirus.
Gelatin, 259. See also specific vaccines.
Generations United, 555t
Genetic engineering, 12t, 16, 17-18
Genetics of vaccine responses, 21, 43-46
somatic hypermutation, 25
Genital warts, 378, 379, 384, 568t
Germinal center reaction, 22, 23-32
heterotypic (cross-protective) responses, 27
homotypic responses, 27
implications for vaccination, 26-32
Germline antibodies, 23
Global Alliance for Vaccines and Immunization, 556t
Gloves, 110, 135
Good Clinical Practice (GCP), 54, 55
Good Laboratory Practices (GLPs), 54, 55
Good Manufacturing Practices (GMPs), 53-55, 54
Good Pharmacovigilence Practices (GPPs), 58
Governmental agencies and committees, 54, 66, 554t
Grace period, 111-112, 154, 155, 163
GRADE approach, 67-70, 71t
Guillain-Barré syndrome, 109t, 262, 267-268, 385
as contraindication/precaution
for DTaP/Tdap vaccines, 336
for influenza vaccines, 267-268, 405, 407
for N meningitidis vaccines, 442
differentiated from rabies, 451
swine flu vaccine and, 80, 81

H1N1, H3N2, H5N1. See Influenza, strains of.
Haemophilus influenzae type b (Hib), 343-348. See also Influenza.
clinical features, 343
societal burden from, 70
correlates of protection, 37, 38t
epidemiology and transmission, 343-344
immunization program, 254, 344
pathogen, 343, 568t
reservoir for, 42-43
vaccines, 12t, 344, 346t-347t
administration errors and remedies, 173t
characteristics and specifics of, 346t-347t
combination vaccines
Pentacel (DTaP-IPV/Hib-T), 345, 449, 538, 540t-546t
Vaxelis (DTaP-HepB-IPV-Hib-OMP), 120t, 540t-546t

Haemophilus influenzae type b (Hib), continued
contraindications/precautions, 345
immunogenicity/efficacy, 344-345
minimum ages and intervals, 156t
optimizing immunity with, 191, 198, 199, 203
recommendations, 70, 345-348
for infants already infected, 165
safety, 345
reportable events, 108t
schedule, 345, 347t
adults, by age, 299
adults, by medical condition/indication, 301
children, age 0-18 years, 290
catch-up, children age 4 months-6 years, 292
storage, 121t
trade names, 367t
ActHIB (Hib-T), 344, 346t-347t
Hiberix (Hib-T), 344-345, 346t-347t
PedvaxHIB (Hib-OMP), 344, 346t-347t
Handling, storage, and transport of vaccines, 117-128
administration of vaccines, 118-119
basics of, 117
during emergencies, 127t
Immunization Tsar/Tsarina, 117, 118t, 134
inventory, 117-118
keeping VFC vaccines separate, 118
signs, 117, 119, 126
storage of vaccines, 119-128, 120t-125t
correct temperature for, 119-126
transportation of vaccines, 126-128
Harm. See Public harm.
HAV. See Hepatitis A.
Havrix (HepA), 120t, 351, 352t-354t
HBIG. See Hepatitis B immune globulin (HBIG).
HBV. See Hepatitis B.
Health care personnel, 113, 216-219
continuing education for, 94
definition of, 216
needlestick injuries/blood exposure, 105-111
postexposure evaluation and prophylaxis, 110
rationale for immunization, 216-217
reporting of adverse events, 94
sharps use and precautions, 105, 110
universal precautions, 110
vaccination recommendations, 94, 113-114, 217-219, 300-301
hepatitis A, 357
hepatitis B, 217-218, 362, 370
influenza, 113, 114, 218, 408
MMR, 218-219, 421
polio, 449
Health care personnel, **continued**

smallpox, 479, 485
Tdap, 219, 327
varicella (VAR), 219, 509
VariZIG, 219
vaccine coverage rates, 192t

Health care providers

addressing concerns about vaccines, 233-285
as trusted source of information, 240-241, 242

Healthcare Effectiveness Data and Information Set (HEDIS), 75, 557t

Healthy People 2020, 91‑92, 133

Heart disease, 296t, 300‑301

Hemagglutinin, 215, 323

Hematopoietic stem cell transplantation (HSCT), 204, 357
revaccination recommendations, 206t‑209t, 348

Hemodialysis, 296t, 300‑301

Hep B, 366t, 370
HepaGam B, 363
Hepatitis A, 349‑360
in Butte County, California, 43, 351
clinical features, 349
correlates of protection, 38t
epidemiology and transmission, 349‑350
herd immunity and, 43, 350
immune globulin, 358t
immunization program, 48, 350‑351
pathogen, 349, 568t
vaccines, 12t, 351, 352t‑354t
administration errors and remedies, 155, 173t
characteristics and specifics of, 352t‑354t, 568t
combination vaccines
   Pediarix (DTaP‑HepB‑IPV), 64t, 538, 540‑546t
   Twinrix (HepA‑HepB), 121t, 538, 548‑551t
   Vaxelis (DTaP‑HepB‑IPV‑Hib‑OMP), 120t, 540‑546t
contraindications and precautions, 369
immunogenicity/efficacy, 363‑368
interchangeability of brands, 370
minimum ages and intervals, 156t, 290
no minimum age for, 163, 365t
purified subunits, 17
recommendations, 362‑363, 369‑373
adult vaccination, 370‑371
for correctional facilities, 362, 370, 371
for diabetics, 186, 370
health care personnel, 217‑218, 362
HIV ‑infection, 187, 370, 371
infants, 362, 369
newborns, 211, 269
postexposure prophylaxis, 169t, 363, 371‑372, 373, 374t‑376t
preterm/low birth weight infants, 214
standing orders for high‑risk individuals, 370‑371
travel, 223, 370
universal infant, child and adolescent immunization, 369‑370
safety, 368‑369
reportable events, 107t
schedule, 366t
adults, by age, 299
adults, by medical condition/indication, 301
children, age 0‑18 years, 290
catch‑up, children age 4 months‑6 years, 293
catch‑up, children age 7‑18 years, 294
seroconversion rates, 351

Hepatitis A, **continued**

storage, 120t
trade names (Havrix, Twinrix, Vaqta), 352t, 548t
Hepatitis B, 361‑376
clinical features, 361‑362
correlates of protection, 37‑40, 38t
epidemiology and transmission, 362
chronic carriers, 361, 362
HBsAg (hepatitis B surface antigen), 17, 37, 361, 363
HBsAg/HBsAb status and, 361‑362, 374t‑376t
testing for, 171, 187, 214, 217‑218, 371‑372
immune globulin (HBIG), 18‑19, 363, 368, 372, 374t‑376t
immunization program, 362‑363
pathogen, 361, 568t
vaccines, 12t, 363, 364‑367t
administration errors and remedies, 173t
characteristics and specifics of, 364t‑367t, 568t
combination vaccines
   Pediarix (DTaP‑HepB‑IPV), 64t, 538, 540‑546t
   Twinrix (HepA‑HepB), 121t, 538, 548‑551t
   Vaxelis (DTaP‑HepB‑IPV‑Hib‑OMP), 120t, 540‑546t
contraindications and precautions, 369
immunogenicity/efficacy, 363‑368
interchangeability of brands, 370
minimum ages and intervals, 156t, 290
no minimum age for, 163, 365t
purified subunits, 17
recommendations, 362‑363, 369‑373
adult vaccination, 370‑371
for correctional facilities, 362, 370, 371
for diabetics, 186, 370
health care personnel, 217‑218, 362
HIV ‑infection, 187, 370, 371
infants, 362, 369
newborns, 211, 269
postexposure prophylaxis, 169t, 363, 371‑372, 373, 374t‑376t
preterm/low birth weight infants, 214
standing orders for high‑risk individuals, 370‑371
travel, 223, 370
universal infant, child and adolescent immunization, 369‑370
safety, 368‑369
reportable events, 107t
schedule, 366t
adults, by age, 299
adults, by medical condition/indication, 301
children, age 0‑18 years, 290
catch‑up, children age 4 months‑6 years, 292
catch‑up, children age 7‑18 years, 294
storage, 121t
trade names (Engerix‑B, Recombivax HB, Heplisav‑B), 364t
Hepatitis B immune globulin (HBIG), 18-19, 363, 368
contraindications/precautions, 369
interval for live vaccines and, 169t
recommendations, 363, 372, 374t-376t
trade names (Nabi-HB, HepaGam B, HyperHEP B S/D), 363
Hepatitis B surface antigen. See under Hepatitis B.
Heplisav-B (Hep-B vaccine), 121t, 363, 364t-367t, 368
Herd immunity, 40-43, 41, 44
Herd immunity threshold, 41-42, 42, 43
Herd severity effect, 43
Herpes zoster. See Zoster (herpes zoster; shingles).
Heterologous host, 16
Heterologous hyperimmune sera, 19
Heterotypic (cross-protective) responses, 27, 36
Hib. See Haemophilus influenzae type b.
Hib-OMP. See PedvaxHIB.
Hib-T. See ActHIB; Hiberix.
Hiberix (Hib-T), 64t, 121t, 173t, 191, 344-345, 346t-347t
HIV (human immunodeficiency virus) infection, 187-191, 271
adults, 191
children/adolescents, 187-191
infants, 187
postexposure prophylaxis, 110
vaccination recommendations, 187-191, 296t, 300-301
for close contacts, 185
contraindications/precautions, 187, 191
H influenzae type b (Hib), 191
hepatitis B, 187, 191, 370, 371
influenza, 191
MMR and VAR, 184, 187-191
N meningitidis, 191, 194-197, 443
pneumonia, 188-190, 191
HLAs (human leukocyte antigens), 24, 45
Homeless people, 297t, 356
Hospital workers, 113-114
HPV. See Human papillomavirus (HPV).
HPV2, HPV4, HPV9. See Human papillomavirus (HPV) vaccines.
Human cell lines, 263
Human immunodeficiency virus. See HIV.
Human leukocyte antigens (HLAs), 24, 45
Human nature, 233-237, 236
Human papillomavirus (HPV), 377-389
cancers and, 255-256, 377-379, 379
clinical features, 377-378
epidemiology and transmission, 378-379
immunization program, 380
in Australia, 384
pathogen, 377, 568t
sexual activity and, 379

Human papillomavirus (HPV), continued
vaccines, 381, 382t-383t
administration errors and remedies, 173t
characteristics and specifics of, 382t-383t, 568t
communicating about, 386-388, 387t
contraindications/precautions, 385
coverage rates in adolescents, 386-388
HPV2 (Cervarix), 380
HPV4 (Gardasil), 380, 381, 384-385
HPV9 (Gardasil 9), 380-388, 382t-383t
recommendations, 380, 382t, 385-388
safety, 384-385
schedule, 380, 382t-383t, 386
adults, by medical condition/indication, 300
children, age 0-18 years, 290
catch-up, children 7-18 years, 294
young adult, by age group, 290, 298
storage, 312t
immunogenicity/efficacy, 381-384
minimum ages and intervals, 157t, 290, 382t-383t
recommendations, 380, 382t, 385-388
adolescents, 290, 294, 298, 385-386
safety, 262, 384-385
Guillain-Barré syndrome, 268, 385
reportable events, 109t
venous thromboembolic events (VTEs), 385
storage, 312t
Human rabies immune globulin (HRIG), 169t, 457, 464t-465t
Hundred-day cough, 324. See also Pertussis.
Hygiene hypothesis, 260
HyperHEP B S/D, 363
HyperRAB S/D (rabies immune globulin), 457
Hyperimmune globulin, 18-19, 169t
HyperTET S/D, 328
Hyporesponsiveness, 23

ICD codes, 147, 148t-149t
IgA, IgG, IgM. See Immune globulin.
IGIM (intramuscular immune globulin)
    intervals for live vaccines and, 168t
for measles, 428
IIV (inactivated influenza vaccine). See Influenza, vaccines, IIV.
Illegal drug users, 228t, 297t, 355, 370, 371
Illusory truth effect, 241-243
Immigrants, 220-221
    proof of vaccinations, 220
Immune deficiency states, 187-204. See also Impaired immunity; Special circumstances.
Immune globulin, 18-19, 168t-170t. See also Antibodies.

botulism (BabyBig), 169t
deficiencies, 191-198, 337, 369, 458, 513
hepatitis A, 168t
hepatitis B (HBIG), 18-19, 169t, 363, 368, 372, 374t-376t
IgA, 19, 21, 30, 369
IgG, 19, 21
IgM, 19, 21, 23, 30
impaired immunity states and, 183
intravenous (IGIV), 165, 168t, 185, 428
isotypes, 19, 21
for measles, 428
for rabies, 457
time course of responses, 30
vaccinia, 484
varicella (VariZIG), 18, 169t, 509, 513, 514-516

Immune memory, 22, 25-26, 31

Immune overload, 256-258, 537

Immune response, 19-36
adaptive immune system, 19, 27
anamnestic response, 22, 26, 31
antibodies, 19-32
    persistence of, 27-31
cytotoxic T cells, 32-36, 34
extrafollicular reaction, 21-23, 22
genetics and, 43-46
germinal center reaction, 22, 23-32
homotypic vs heterotypic, 27
innate immune system, 23-32, 27
    stimulating, 26-27, 27, 30
priming and boosting, 26-27, 30, 31
time course of, 26-27, 30

Immune thrombocytopenia (ITP), 237, 275, 424

Immunology, basic, 19-36. See also Immune response.

Immunosuppression. See Impaired immunity.

Immunosuppressive medications, 192t, 201
steroids, 200

Imogam Rabies-HT (rabies immune globulin), 457

Imovax Rabies (RAB-HDC), 454t-456t

Impact of vaccines, 48-50, 52t

Impaired immunity, 183-185
general considerations, 183-185
    close contacts, immunization of, 185
differences in immunocompromised states, 183-184
    official recommendations vs package insert, 185
    risks vs benefits, 183
suboptimal immune responses, 184-185
guidelines for vaccination, 183-185
immune deficiency states, 187-204, 296t
    asplenia, 199-200, 296t
    B-cell (humoral) deficiencies, 191-198
cancer chemotherapy, 203-204
complement deficiencies, 199
disease-modifying antirheumatic drugs (DMARDs), 200-201
hematopoietic stem cell transplantation, 204, 206t-209t
HIV infection, 187-191, 296t
phagocyte disorders, 183-184, 198-199
solid organ transplantation, 192t, 201-204, 202
steroids, 200
T-cell deficiencies, 198

Immunization, continued
primary, 26-27, 30
reactions to. See Adverse events.
schedules. See Schedules for immunization.
standards. See Standards, principles, and regulations.
Immunization Action Coalition (IAC), 556t
Immunization Information Systems (IISs), 132-133
Immunization platforms, 287-288, 302t
Immunization practices, standards and guidelines for, 91-152
Immunization programs, 46-50. See also specific vaccines.
    childhood, impact of, 50, 52t
control/elimination/eradication/extinction of disease, 46-48, 49t
goals of, 46-48, 91-92
impact of, 48-50, 49t, 52t
triumphs of, 49t

Immunization Safety Review Committee (ISRC), 81

Immunization Tsar or Tsarina, 117, 118t, 134

Impaired immunity. See Impaired immunity.

Immunogenicity, 31-32, 36. See also Immune response; specific vaccines.
clinical trials to determine, 56, 56
efficacy and, 36
immunogenicity bridging, 56

Immunoglobulins. See Immune globulin.

Immunology, basic, 19-36. See also Immune response.

Immunosuppression. See Impaired immunity.

Immunosuppressive medications, 192t, 201
steroids, 200

Imogam Rabies-HT (rabies immune globulin), 457

Imovax Rabies (RAB-HDC), 454t-456t

Impact of vaccines, 48-50, 52t

Impaired immunity, 183-185
general considerations, 183-185
    close contacts, immunization of, 185
differences in immunocompromised states, 183-184
    official recommendations vs package insert, 185
    risks vs benefits, 183
suboptimal immune responses, 184-185
guidelines for vaccination, 183-185
immune deficiency states, 187-204, 296t
    asplenia, 199-200, 296t
    B-cell (humoral) deficiencies, 191-198
cancer chemotherapy, 203-204
complement deficiencies, 199
disease-modifying antirheumatic drugs (DMARDs), 200-201
hematopoietic stem cell transplantation, 204, 206t-209t
HIV infection, 187-191, 296t
phagocyte disorders, 183-184, 198-199
solid organ transplantation, 192t, 201-204, 202
steroids, 200
T-cell deficiencies, 198
Impaired immunity, continued
live vaccine use in households of, 166-167
live vaccines generally contraindicated for, 178
newborns, 186, 211
optimizing immunity
to *H influenzae*, 191, 198, 199, 203
to *N meningitidis*, 191, 194-197, 199
to *S pneumoniae*, 186, 188-190, 191, 198, 199, 201, 203
other predisposing conditions, 186, 204-207
passive immunoprophylaxis for, 185
vaccine coverage rates, 192t-193t
vaccine recommendations, 183-204, 296t, 300-301, 345-346, 357, 358t
general considerations, 183-187
*N meningitidis*, 434
pneumococcal vaccines, 188-190
Inactivated vaccines, 12t, 17-18
characteristics of, 14t-15t
component vaccines, 17-18
grace period and, 155
intervals for vaccination, 154-155
purified subunits, 12t, 17
vs live vaccines, 14t-15t, 35
whole agent, 12t, 17
Inborn errors of metabolism, 214-215
Indications, 68t-69t
labeled indications, 59, 64t-65t
vs official recommendations, 62, 64t-65t, 68t-69t
Infanrix (DTaP), 329, 330t-332t
storage, 120t
Infants. See also *Children; Newborns.*
birth vaccinations, 211, 290, 362, 368, 369
botulism immune globulin (BabyBig), 169t
cocooning strategy, 130, 326-328
hepatitis B vaccination, 211, 362, 368, 369
HBsAg/HBsAb testing, 372
post-exposure prophylaxis, 371-372
standing orders for, 369
Hib infection, 255
vaccinating for, 165, 345
HIV and, 187
infant-toddler immunization platform, 302t
maternal antibody protection, 18, 204
maternal immunization, benefits for, 130
newborns, 186, 211
pain relief for, 142
pertussis immunization, 327
pertussis in, 130, 205
preterm and low birth weight, 214, 475
rotavirus vaccination, 166, 469, 471t-472t, 475
Infants, continued
routine immunization schedule, 290
susceptibility gap, 204
varicella/VariZIG, 514, 516
Infectious Diseases Society of America (IDSA), 95, 555t
Inflammatory reaction, 24, 258
Influenza, 391-410
clinical features, 392-393
correlates of protection, 38t
deaths from, 392, 393-394, 394
economic burden of, 393-394, 395
epidemics/pandemics, 62, 391-392
2009 A(H1N1), 62, 267-268, 276, 392, 394
Spanish flu (1918), 391-392
epidemiology and transmission, 393-394
annual mortality, 393-394, 394
immunization program, 394-397, 396
cost-effectiveness of, 397
coverage goals, 92
school-located vaccination, 132
pathogen, 391-392, 568t
antigenic shift and drift, 391
reassortment and, 391, 401
strains, 391-392
A, H, and N, 391, 401
A(H1N1), 267, 276-277, 391-392, 397, 404
special surveillance efforts, 80
A(H3N2), 392, 397, 404
A(H5N1, avian flu), 391, 392, 401
vaccines, 397-401, 398t-400t
administration errors and remedies, 173t-174t
annual production of, 401
characteristics and specifics of, 398t-400t, 568t
“egg-free” (Flublok, Flucelvax), 398t, 401
IIV (inactivated), 398t-400t, 401
A (H5N1) vaccine, against avian flu, 401
administration errors and remedies, 173t
contraindications/precautions, 405
“egg-free” vaccines (Flublok, Flucelvax), 398t, 401
Fluad, 398t, 401
high-dose (Fluzone High-Dose), 215, 397, 399t, 403
immunogenicity/efficacy, 402-403
jet injector for, 142
safety, 404-405
storage, 121t
immunogenicity/efficacy, 402-404
effectiveness, 402
LAIV (live-attenuated), 12t, 398t, 401
administration errors and remedies, 174t
contraindications/precautions, 191, 200, 406-407
Influenza, continued

immunogenicity/efficacy, 403-404
intranasal administration of, 142, 144
reassortment backbone, 401
safety, 405-407
storage, 121t
quadribivalent vaccines, 397
recommendations, 298, 394-397, 396, 407-408
adults, 298, 394-397, 408
adults over 65 years, 215-216, 298, 396, 397, 403
annual vaccination, 407
children, 394, 396, 407-408
children on aspirin therapy, 408
during pregnancy, 210, 212t, 408
health care personnel, 113, 114, 218, 408
high risk/priority patients, 408
minimum ages and intervals, 157t, 290
for travel, 223
universal vaccination, 396, 408
safety, 404-407
Bell's palsy, 276
egg allergy and, 405
Guillain-Barré syndrome, 267-268, 405, 407
miscarriage, 278
MS, 268-269
narcolepsy, 276-277
schedule, 407-408
adults, by age, 299
adults, by medical condition or indication, 300
children, age 0-18 years, 290
shortages of, 86-87
storage of, 121t
trade names, 398t-400t
Afluria, 398t
Flud, 398t, 401
Fluarix, 398t
Flublok, 398t, 401
Flucelvax, 398t, 401
Flulaval, 398t
Flumist, 121t, 398t
Fluzone, 399t
Fluzone High-Dose, 215, 397, 399t

Injury. See National Childhood Vaccine Injury Act; Vaccine Injury Compensation Program.

Innate immunity, 23-32, 27
adjuvants and, 26, 27
stimulating, 26-27, 27, 30
Institute for Vaccine Safety, Johns Hopkins, 556t
Institute of Medicine (IOM), 81
Interferon-gamma release assay (IGRA), 484, 513, 524

International adoptees, refugees, and immigrants, 220-221, 350
Internet resources, 554t-557t
Intervals for vaccinations, 153-167, 156t-162t
doses in a series, 163-164
doses of same vaccine, 155-163
grace period, 111-112, 154, 155
inactivated vaccines, 154-155
lapse in series and, 163-164
live vaccines, 154
between live vaccines and antibody-containing blood products, 165-166, 168t-170t
minimum intervals and ages, 19, 153-167, 156t-162t
simultaneous administration, 153-154
Intradermal administration, 141, 142
Intramuscular administration of vaccines, 137-142, 141
Intravenous immune globulin (IGIV), 168t
Intussusception, 178, 237, 274-275, 468, 474
Inventory of vaccines, 117-118
keeping VFC vaccines separate, 118
rotation of stock, 117
IPOL (IPV), 121t, 448t. See also Polio, vaccines.
IPV. See Polio, vaccines.
Isotypes, 19, 21, 23
isotype switching, 23, 25
ISRC (Immunization Safety Review Committee), 81
Ixario (JEV-VC), 121t, 413, 414t-415t

Japanese encephalitis, 411-416
clinical features, 411
correlates of protection, 38t
epidemiology and transmission, 226, 412
immunization program, 412-413
pathogen, 411, 568t
vaccines, 12t, 413, 414t-415t
characteristics and specifics of, 414t-415t
contraindications/precautions, 415
immunogenicity/efficacy, 413
JEV-MB, 412, 413
JEV-VC (Ixario), 413, 414t-415t
recommendations, 415-416
laboratory workers, 416
for travel, 226, 415
safety, 413-415
schedule, 414t
storage, 121t
trade name: Ixario (JEV-VC), 414t
Jenner, Edward, 16
JEV. See Japanese encephalitis.
Kawasaki disease, 168t, 272-273
Kidney failure/disease, 186, 296t, 300-301, 470
Kinrix (DTaP-IPV), 120t, 172t, 540t-546t
Labeled indications, 59
vs official recommendations, 62, 64t-65t
Laboratory workers, vaccination of, 111, 228t, 314t, 355, 416,
443, 449, 460t, 484, 505, 524
LAIV (live-attenuated influenza vaccine). See Influenza,
vaccines, LAIV.
Langerhans cells, 24
Language and meaning, 245t
Latex, 177. See also specific vaccines.
Licensure. See Vaccine development and licensure.
Life-course immunization, 215
Live vaccines, 11-16, 12t-13t, 21
attenuation of, 11-16
characteristics of, 14t-15t, 21
given enterically, 304
grace period and, 154, 155
intervals for receipt of antibody-containing products, 165-166,
168t-170t
intervals for vaccinations, 154
in pregnancy and immunocompromised persons, 14t, 166-167,
177-178, 210-211, 212t
vs inactivated vaccines, 14t, 35
Liver cancer, 362
Liver disease, 186, 296t, 300-301, 356, 358t, 370
Lockjaw. See Tetanus.
Long-term care facilities, 229t
Lung disease, vaccinations recommended, 300-301
Lyme disease, 276
correlates of protection, 38t

Mad cow disease (MCD), 270
Major histocompatibility complex (MHC), 43-45
class I molecules (MHC-I), 32, 34, 35
class II molecules (MHC-II), 22, 24, 25, 31, 34
Mandates and exemptions for immunization, 111-114
Mandatory reporting of adverse events, 77, 94, 101, 103t
Manufacturers of vaccines, 87, 557t
financial risk for, 53
interchangeability of vaccines, 164
number of, 87
vaccine design defect claims, legal immunity from, 100-101
Measles, Mumps, Rubella, continued
measles endemic in UK, 221
measles outbreaks in US, 249-254, 253
evidence/proof of immunity, 210, 426t-427t
immune globulin (for measles), 428
immunization program, 420-421
presumption of immunity with, 167-171
pathogens, 417-418, 568t
elimination of measles and rubella (Americas), 47, 49t, 424
resurgence of, 48, 249-254, 420, 421-424
measles, 249-254, 253, 421-422
mumps, 48, 420, 423-424
rubella
congenital rubella syndrome (CRS), 419, 424
declared eliminated from the Americas, 424
proof of immunity, 210, 426t
vaccines (MMR), 12t, 421, 422t-423t
characteristics and specifics of, 422t-423t
combination vaccine (MMRV), 420, 539, 548t-551t.
See also MMRV vaccine.
vs MMR plus VAR, 420, 538-539
contraindications/precautions, 425
evidence/proof of immunity, 210, 426t-427t
immunogenicity/efficacy, 421-424
interval for receipt of antibody-containing products, 165-166,
168t-170t
recommendations, 64t-65t, 425-428
health care personnel, 218-219, 421
HIV-infected individuals, 187-191
postexposure prophylaxis (measles), 428
safety, 273, 424-425
autism concerns, 263-264
febrile seizures, 274, 424
ITP, 275, 424
reportable events, 106t-107t
schedule, 422t-423t
adults, by age, 298
adults, by medical condition/indication, 300
children, age 0-18 years, 290
catch-up, children age 4 months-6 years, 293
catch-up, children age 7-18 years, 294
minimum ages and intervals, 158t, 163, 290
storage, 122t, 124t
trade name (M-M-R II), 422t
Medicaid, 86, 554t
Medical home, 129-130
Medicare, 86, 554t
Membrane attack complex, 19-21, 20
Memory B-cells, 22, 25-26, 27, 31
Memory T and Th-cells, 26, 27
Men who have sex with men, 228t, 297t, 300-301, 355, 370
Menactra (MenACWY-D), 40, 174t, 432, 435, 436t-439t
  immunogenicity, 440
  minimum ages and intervals, 158t
  recommendations, 301, 432, 434
  safety, 268, 441-442
  schedules, 194-195, 290, 294, 299
  storage, 122t
MenB, 12t, 175t, 434
  schedules, 194-195, 290, 299
  use of same product in series, 164
MenB-4C (Bexsero), 175t, 435, 436t-439t
  adjuvant, 28t
  immunogenicity, 441
  minimum ages and intervals, 157t
  recommendations, 64t, 301, 433, 434
  schedules, 175t, 290
  storage, 122t
MenB-FHbp (Trumenba), 175t, 433, 435, 436t-439t
  immunogenicity, 441
  minimum ages and intervals, 158t
  recommendations, 64t, 433
  schedules, 175t
  storage, 122t
Meningitis, 431-432. See also Neisseria meningitidis.
  aseptic, 411, 419
  bacterial, pneumonia and, 489
  Haemophilus influenzae type b and, 343
  invasive meningococcal disease (IMD), 226, 432
  meningococcal, 431-432
  mumps and, 419
  polio and, 445
Meningococcal vaccines. See Neisseria meningitidis.
Meningitis, 431-432. See also Neisseria meningitidis.
Meningitis, 431-432. See also Neisseria meningitidis.
Menveo (MenACWY-CRM), 174t, 435, 436t-439t
  Bell's palsy and, 276, 441
  immunogenicity, 440-441
  safety, 441
  storage, 122t
Mercury (thimerosol) in vaccines, 264-265
Methotrexate, 201
MF59 (adjuvant), 29t, 258
MHC, MHC-I, MHC-II. See Major histocompatibility complex.
Military personnel, 46, 228t, 443
  adenovirus vaccination, 307
  anthrax vaccination, 311, 313
  smallpox vaccination, 479, 484
Minimum age and intervals for vaccination, continued
  exception: no minimum age for HepB or RAB, 164
Missed opportunities, 129, 178
Morbidity and mortality. See Deaths.
Morbidity and Mortality Weekly Report, 67
Morticians, vaccination of, 228t
MPSV4 (Menomune-A/C/Y/W-135), 433, 434, 440
Mucosal surfaces, 21, 154, 166
Multiple sclerosis, 268-269
Multiple vaccines, simultaneous administration of, 64t, 94, 137, 153-154. See also Combination vaccines.
  exceptions, 153
  immune overload concept, 256-258
Mumps. See Measles, Mumps, Rubella.
Mycobacterium bovis, 16
Nabi-HB, 363
Narcolepsy, 276-277
National Adult Immunization Plan, 97
National Center for Immunization and Respiratory Diseases (NCIRD), 62, 66, 76
National Childhood Vaccine Injury Act, 77, 81, 97-101
National Coalition for Adult Immunization, 96
National Drug Codes (NDCs), 147
National Foundation for Infectious Diseases, 556t
National Health Interview Survey (NHIS), 75, 557t
National Immunization Survey (NIS), 73, 557t
National Institute of Allergy and Infectious Diseases (NIAID), 554t
National Institutes of Health (NIH), 66
National Meningitis Association, 556t
National Notifiable Disease Surveillance System (NNDSS), 76, 557t
National Respiratory and Enteric Surveillance System (NREVSS), 76
National Vaccine Advisory Committee (NVAC), 66, 71, 554t
adult immunization standards, 95-97, 98t-99t
immunization registries, 133
pediatric immunization standards, 92-95
National Vaccine Error Reporting Program (VERP), 167
National Vaccine Injury Compensation Program. See Vaccine Injury Compensation Program (VICP).
National Vaccine Plan, 71
National Vaccine Program Office (NVPO), 66, 71, 554t
Native Americans and Alaska Natives, 229t
Natural infection, vs immunization, 255-256
Natural killer cells, 19-21
Necessity of vaccines, 254-255
Needle length, 142, 143t
Needlestick injuries, 105
Neighborhood, immunization, 129-130
Neisseria meningitidis, 431-444
clinical features, 431-432
correlates of protection, 38t
epidemiology and transmission, 432-433
serogroups, 432-433, 435, 436t
immunization program, 433-435, 434
cost-benefits, 433
pathogen, 431, 568t
vaccines, 435-440, 436t-439t
adjuvants, 28t
administration errors and remedies, 174t-175t
characteristics and specifics of, 436t-439t, 568t
combination vaccine: Vaxelis (DTaP-HepB-IPV-Hib-OMP), 120t, 540t-546t
contraindications/precautions, 153, 442
immunogenicity/efficacy, 440-441
licensure of, 40, 268
MenACWY, 12t, 194-195, 434
MenACWY-CRM, 40, 436t-439t, 440-441
Bell's palsy and, 276, 442
immunogenicity, 440-441
MenACWY-D, 40, 434, 436t-439t, 440
immunogenicity, 440
MenB, 12t, 194-195, 434
MenB-4C, 435, 436t-439t
MenB-FHbp, 433, 436t-439t
recommendations, 64t, 435
minimum ages and intervals, 157t-158t, 290
MPSV4, 433, 434, 440
reportable events, 109t
optimizing immunity with, 194-197
recommendations, 64t, 433-435, 434, 442-443
adolescents, 95, 290, 432, 433, 434
college students, 433, 434, 443
MPSV4, continued
during pregnancy, 212t
tavel, 227, 443
universal adolescent immunization, 432, 434, 442-443
use of same product in series, 164
safety, 441-442
Bell's palsy, 276, 442
Guillain-Barré syndrome, 268, 442
reportable events, 109t
schedule, 442-443
adults, by age, 299
adults, by medical condition/indication, 301
children, age 0-18 years, 290
catch-up, children age 7-18 years, 294
storage, 122t
trade names, 436t
Bexsero (MenB-4C), 436t
Menactra (MenACWY-D), 435, 436t
Menveo (MenACWY-CRM), 435, 436t
Trumenba (MenB-FHbp), 436t
Vaxelis (DTaP-HepB-IPV-Hib-OMP), 540t
Nephrotic syndrome, 186
Neutralization of pathogens, 19-21, 20
New Vaccine Surveillance Network (NVSN), 76
Newborns, 18, 186, 211. See also Infants.
Hepatitis B vaccination, 211, 214
maternal chickenpox, VariZIG for, 516
neonatal tetanus, 324, 325
vaccinations given at birth, 211, 290, 362, 368, 369
Nomenclature, vi-vii, 568t-569t
Noninferiority, 56, 538
Nursing homes, coverage survey, 75

Occupational Safety and Health Administration (OSHA), 105-111
Office visit, coding and billing example, 147, 148t-149t
Older adults, 215-216, 298-299
immunization platform, 302t
immunization schedule, 298-299
influenza immunization, 298, 325-326, 396, 397, 403
life-course immunization, 215
pneumonia immunization, 216, 495, 496
zoster vaccination, 216, 535
Opsonization, 19-21, 20
OPV. See Polio, vaccines.
Oral administration of vaccines, 142, 144
OSHA (Occupational Safety and Health Administration), 105-111
Otitis media, 508
Overimmunization, 539
Package insert (PI), 59-62, 153-154, 185
labeled indications, 59, 64t-65t
Pain (of administration), dealing with, 142-145
Palivizumab (Synagis), 19, 166, 168t
Pandemrix, 276-277
Parents of Kids With Infectious Diseases, 556t
Partial doses, 177
Passive immunization, 11, 18-19, 185
during pregnancy, 18
potential inactivation of vaccines, 19
Pasteur, Louis, 16, 17
Pathogens, 568t-569t. See also pathogen subentry under specific agents.
antibody effects on, 19-21, 20
pathogen-specific antibodies and T-cells, 19
pathogen-specific molecular patterns (PAMPs), 24
reservoirs for, 42
Patient Protection and Affordable Care Act (ACA), 82
Patternicity, 236
Pediarix (DTaP-HepB-IPV), 64t, 120t, 540t-546t
safety, 538
Pediatric immunization standards, 92-95. See also Children; Infants.
Pediatric Infectious Diseases Society, 555t
PedvaxHIB (Hib-OMP), 121t, 167, 191, 344, 345, 346t-347t
adjuvant, 28t, 258
Pentacel (DTaP-IPV/Hib-T), 120t, 173f, 345, 449, 540t-546t
Personal belief exemptions, 112-113
Pertactin (PRN), 17, 323, 330t
Pertussis, 323-341. See also Diphtheria, tetanus, and pertussis.
clinical features, 324-325
correlates of protection, 40
epidemiology and transmission, 325-326
prevention for infants by maternal immunization, 130
immunization program, 326-328, 327
pathogen, 323, 325, 568t
pertussis toxin (PT), 323-325
resurgence of, 48, 249
vaccines, 328, 330t-332t, 568t
combination vaccines, 538-539, 540t-546t
contraindications/precautions, 333-337
immunogenicity/efficacy, 328-333
recommendations, 326-328, 327, 337-338
adult. See Tdap vaccines.
children/infants. See DTaP vaccines.
for pregnant women, 130
safety, 333-337
allergies and, 261, 333, 336
brain damage concerns, 266-267
encephalopathy, 177, 269, 333, 336
reportable events, 106t
Pertussis, continued
schedule, 331t, 337-338
trade names, 330t
Adacel (Tdap), 330t-332t
Boostrix (Tdap), 330t-332t
Daptacel (DTaP), 330t-332t
Infanrix (DTaP), 330t-332t
whole-cell, 17
waning immunity and, 48, 329
Phagocyte disorders, 183-184, 198-199
Phagocytes/phagocytosis, 19, 20, 24
Pharmacists
American Pharmacists Association, 555t
vaccine administration by, 129-130
Phase 1, 2, 3, and 4 trials, 55-58, 56
“Pink Book” (Epidemiology and Prevention of Vaccine-Preventable Diseases), 67
Placebo, 56
Plasma cells, 21-23, 22, 27-30
longevity of, 31
Pneumococcal vaccines, 490-496, 492t-493t
characteristics and specifics of, 491, 492t-493t, 569t
contraindications/precautions, 495
correlates of protection, 39t
immunization program, 490-491
cost-effectiveness of, 491
herd immunity and, 491
impact of, 43, 44, 48
immunogenicity/efficacy, 491-495
CAPITA study, 216, 494
minimum ages and intervals, 158t, 188-189, 290
optimizing immunity with, 188-190
PCV7, 490, 491-494
serotype replacement and, 43, 45, 48, 490
PCV13 (Prevnar 13), 490-491, 492t-493t, 494-496
administration errors and remedies, 175t
immunogenicity/efficacy, 494
minimum age and intervals, 153, 158t, 188-189, 290
optimizing immunity with, 188-190
safety, 495
schedule, 492t, 495-496
adults, by age, 299
adults, by medical condition/indication, 301
children, age 0-18 years, 290, 495-496
catch-up, children, age 4 months-6 years, 293
storage, 122t
PPSV23 (Pneumovax 23), 491, 492t-493t, 494-496
administration errors and remedies, 175t
immunogenicity/efficacy, 216, 494-495
minimum age and intervals, 153, 158t, 188-189
Pneumococcal vaccines, continued
optimizing immunity with, 188-190
safety, 495
schedule, 492t
adults, by age, 299
adults, by medical condition/indication, 301
storage, 122t
recommendations, 490-491, 495-496
older adults, 216, 495, 496
replacement disease and, 490
safety, 495
reportable events, 108t
serotype replacement, 43, 45, 490
storage, 122t
Pneumonia, 255, 489-497. See also Pneumococcal vaccines.
clinical features, 489-490
invasive pneumococcal disease (IPD), 489-490
epidemiology and transmission, 490
immunization program, 490-491
impaired immunity and, 186
mortality from, 216, 490
optimizing immunity to, 188-190
pathogen, 489, 569t
serotype replacement, 43, 45, 490
Pneumovax 23 (PPSV23), 492t-493t. See also Pneumococcal vaccines, PPSV23.
Policy. See Vaccine policy.
Polio, 445-450
clinical features, 445
correlates of protection, 38t
epidemiology and transmission, 445-446
Americas certified free of, 47, 49t, 446, 447
endemic countries (in 2019), 447
international spread of polio, 223-226, 447
OPV-derived polio cases, 47, 185, 446
underimmunized individuals and, 446
immunization program, 446-447
pathogen, 445, 568t
proof of immunity, 447, 449
vaccines, 447, 448t
characteristics and specifics of, 448t
combination vaccines, 540t-546t
Kinrix (DTaP-IPV), 120t, 540t-546t
Pediarix (DTaP-HepB-IPV), 64t, 540t-546t
Pentacel (DTaP-IPV/Hib-T), 120t, 449, 540t-546t
Quadracel (DTaP-IPV), 540t-546t
Vaxelis (DTaP-HepB-IPV-Hib-OMP), 120t, 540t-546t
immunogenicity/efficacy, 447
inactivated (IPV), 448t
combination vaccines, 540t-546t

Polio, continued
contraindications/precautions, 449
immunogenicity/efficacy, 447
minimum ages and intervals for, 157t, 290
recommendations, 449-450
safety, 447-449
schedule, 448t, 449-450
children, age 0-18 years, 290
catch-up, children 7-18 years, 294
catch-up, children age 4 months-6 years, 293
storage, 121t
oral (OPV), 446-447
2-valent, 446, 447
3-valent, 446-447, 449
destruction of vaccine stocks, 47
polio cases caused by, 47, 185, 446
reimmunization recommended, 449
proof of immunity, 447, 449
recommendations, 446-447, 449-450
for travel, 223-226, 449
safety, 447-449
AIDS not caused by, 271
reportable events, 107t, 109t
SV40 and, 270-271
trade name (IPOL), 121t, 448t
Polyclonal immune globulin, 18
Polysaccharide antigens, 21-23, 22, 31-32
immune response to, 21-23, 22
Polysaccharide vaccines, 17-18, 31-32, 33t
advantages of, 31-32, 33t
protein-polysaccharide vaccines, 22
pure, 17-18
Postherpetic neuralgia (PHN), 256, 527, 528
PPSV23. See Pneumococcal vaccines, PPSV23.
Precautions. See Contraindications and precautions.
Prefilled syringes, 119, 177
Pregnancy, 204-211, 212t-213t, 296t
hepatitis B antigen (HBsAg), testing for, 371-372
as indication for vaccination, 130, 177, 205, 212t, 296t
passive immunization in, 18, 163, 211
rubella, proof of immunity, 210, 426t
smallpox, disease effects on, 477
vaccination during, 204-211, 212t-213t, 296t, 300-301
birth defect concerns, 177, 205, 277-278
contraindications/precautions, 166, 177-178, 210, 212t, 296t, 425, 449, 486t, 531
indications for, 130, 177, 205, 212t, 296t
influenza, 210, 212t, 300, 406, 408
Pregnancy, continued
live vaccines, 14t, 210
generally contraindicated during pregnancy, 177, 210, 212t
exceptions to, 210, 212t
for household contacts, 166-167, 210
maternal immunization platform, 205, 302t
miscarriage concerns, 277-278
pertussis, 130
Tdap, 205, 212t, 300, 327, 328, 338
varicella, 210, 212t, 514
VariZIG, 211, 514-516
yellow fever, 177, 212t, 524, 525
vaccine coverage rates, 192t
PREP Act, 101, 484
Preservatives, 259. See also specific vaccines.
Prevention of infection, 19, 35
vs prevention of disease, 35, 76
Prevnar, 122t, 490-491, 492t-493t. See also Pneumococcal vaccines, PCV13.
Primary immunization, 26-27, 30
Primary ovarian insufficiency (POI), 278-279
Primary vaccine failure, 31, 60t-61t
Priming and boosting, 26-27, 30, 31
PRISM (Post-licensure Rapid Immunization Safety Monitoring), 79
ProQuad, 124t, 548t-551t. See also MMRV vaccine (ProQuad).
Protein-polysaccharide vaccines, 31-32
advantages of, 31-32, 33t
Public harm, from fear and refusal of vaccines, 249-254
Public health, 46-50. See also Concerns about vaccines, addressing.
impact of vaccines, 48-50, 49t, 52t
risks of refusal of vaccination, 249-254
Public health emergency
preparedness for, 62, 101
vaccine stockpiles for, 62, 87, 401, 483
Public Readiness and Emergency Preparedness Act, 101, 484
Public safety workers, vaccination of, 229t, 370
Purified subunits, 12t, 17
Purple Book, vi

Quadracel (DTap-IPV), 120t, 172t, 540t-546t
Questions about vaccines. See Concerns about vaccines.

RAB-HDC (Imovax Rabies), 122t, 454t-456t, 457
RAB-PCEC (RabAvert), 122t, 454t-456t, 457
RabAvert (RAB-PCEC), 122t, 454t-456t
Rabies, 451-465
clinical features, 451-452
correlates of protection, 38t
epidemiology and transmission, 226, 452
successful treatment, 452

Rabies, continued
immune globulin (HRIG), 169t, 457, 464t-465t
immunization program, 453
pathogen, 451, 569t
vaccines, 12t, 453-457, 454t-456t
administration errors and remedies, 175t
characteristics and specifics of, 12t, 454t-456t, 569t
contraindications/precautions, 457-458
immunogenicity/efficacy, 457
no minimum age for, 163
postexposure prophylaxis, 65t, 453, 455t, 462t-465t
with immune globulin (HRIG), 169t, 457, 464t-465t
regimens for, 464t-465t
wound cleansing, 464t-465t
pre-exposure vaccination (prophylaxis), 453, 455t, 460t-461t
recommendations, 453, 458, 460t-465t
animal evaluation and, 462t-463t
for animal handlers, 111, 460t
for travel, 226
safety, 457-458
schedule, 455t, 460t
storage, 122t
trade names (Imovax Rabies, RabAvert), 454t
wildlife, oral vaccination of, 452
Rabies immune globulin, human (HRIG), 457, 464t-465t
interval for live vaccines and, 169t
Rapid cycle analysis, 79
Reactions to vaccines. See also Adverse events.
administration errors and corrections, 167, 171t-176t
anaphylaxis, 106t-107t, 146
injection-site. See specific vaccines.
Reassortment, 16, 391, 401
Recall and tracking systems, 128-129
Recombinant DNA technology, 17-18
Recombinant subunit vaccines, 12t, 17-18
Recombivax HB (HepB), 121t, 363, 364t-367t, 370
Recommendations, vii, 62-72, 153-181. See also Administration of vaccines; specific vaccines.
AAP, 70-71
ACIP, vii, 63-70, 539
administration errors and corrections, 167, 171t-176t
adult immunization, 67
agencies involved with, 62-72, 66
Category A or B, 70, 72t
child/adolescent schedule, 67
considerations for making, 70
counterindications and precautions, 177-178
disease burden and, 70
Evidence to Recommendations (EtR) framework, 67-70
General Best Practice Guidelines, 67
general recommendations, 67, 153-181
Recommendations, continued
GRADE approach, 67-70, 71t
intervals for receipt of antibody-containing blood products, 165-166, 168t-170t
minimum age and intervals for vaccinations, 19, 153-167, 156t-162t, 290
official, vs labeled indications, 62, 64t-65t, 68t-69t
routine schedules, 287-302. See also Schedules for immunization.
special circumstances, 183-232
ten simple rules, 153-167
terminology in reference to, 68t-69t
vaccination of persons who have had the disease, 165, 181t
vaccine handling, storage, and transport, 117-128
vs package insert, 59-62, 64t-65t, 153-154, 185
“when in doubt, vaccinate,” 165
working groups for, 67
“Red Book” (Report of the Committee on Infectious Diseases), 71
Refrigerator, storage of vaccines in, 119-126, 120t-123t
Refusal of vaccination, 246-248, 246
forms for, 247
modified schedules, 247
physician dismissal of vaccine-refusing families, 247-248
public harm from, 249-254
Registries. See Immunization Information Systems.
Regulations. See Standards, principles, and regulations.
Religious exemptions, 112-113
Reminder, recall, and tracking systems, 128-129
Report of the Committee on Infectious Diseases. See “Red Book”.
Reportable Events Table, 97, 106t-109t
Reporting of adverse events, 77-79, 106t-109t
mandatory reporting, 77, 94, 101, 103t
to VAERS, 77-79, 101, 103t, 171t
Respiratory disease
adenovirus and, 303
vaccinations recommended, 300-301
Respiratory syncytial virus (RSV), antibody against (palivizumab, Synagis), 19, 166, 168t
Reverse genetics, 401
Reverse vaccinology, 18
Reye syndrome, 138t, 228t, 406, 408, 508, 513
RhoGAM, 169t
Risks and benefits of vaccines, 76, 233-244
communicating about, 233-244, 240t-241t
costs of public concern, 249-254
human nature and, 233-237, 236
risks vs benefits, balancing, 237, 238t
Rotarix (RV1), 122t, 144, 469-474, 470t-472t. See also Rotavirus, vaccines.
RotaShield (RRV-TV), 237, 274, 468
RotaTeq (RV5), 122t, 144, 274, 469-474, 470t-472t.
See also Rotavirus, vaccines.
Rotavirus, 467-476
clinical features, 467
societal burden, 70
epidemiology and transmission, 468
immunization program, 237, 468-469
cost-effectiveness, 468-469
decline in rotavirus activity due to, 473-474, 473
pathogen, 467, 569t
vaccines, 469, 470t-472t
characteristics and specifics of, 470t-472t, 569t
contraindications/precautions, 469, 474
development cost of, 53
heterologous host, 16
immunogenicity/efficacy, 469-474, 473
minimum ages and intervals, 19, 159t, 166, 290
oral administration, 142, 144
reassortment and, 16
recommendations, 65t, 469, 475
infants, 469, 471t-472t, 475
preterm infants, 214, 475
RRV-TV, 237, 274, 468
RV-1 (Rotarix), 12t, 123t, 469-474, 470t-472t
safety, 274-275, 474
RV-5 (RotaTeq), 12t, 16, 123t, 469-474, 470t-472t
development cost, 53
safety, 274-275, 474
safety, 238t, 239t, 474
horizontal transmission, 474
intussusception concerns, 237, 274-275, 468, 474
porcine circovirus contamination, 273
reportable events, 108t
schedule, 471t-472t
children, age 0-18 years, 290
catch-up, children, 4 months-6 years, 292
storage, 123t
Routes of administration, 137-142. See also Administration of vaccines.
errors in, 167
Routine schedules. See Schedules for immunization.
RSV. See Respiratory syncytial virus (RSV).
Rubella. See Measles, Mumps, Rubella.
Rubeola. See Measles.
Rules for vaccination, 153-167. See also Recommendations.
RZV (recombinant zoster vaccine). See Zoster.
Sabin, Albert, 11
Sabin Vaccine Institute, 556t
Safety of vaccines, 237-279, 260. See also Adverse events; Vaccine Safety Net; and specific vaccines.

communicating about, 237-244, 240t-241t
meaning of safety, 237
monitoring of safety, 76-81
on-time schedules, 260
postmarketing surveillance, 58, 76
safety does not mean harmless, 237
Vaccine Safety Net, 76-81, 78
Salicylates. See Aspirin.
Salk, Jonas, 17
Salmonella enterica, 499
Salmonella typhi, 16, 221, 499, 569t. See also Typhoid fever.
Schedules for immunization, 287-302. See also specific vaccines.
adults, by age group, 298-299
adults, by medical indication, 300-301
children, age 0-18 years, 290-291
catch-up schedule, children age 4 months-6 years, 292-293
catch-up schedule, children age 7-18 years, 294-295
children and adolescents, routine immunizations, 290-291
children and adolescents, special immunizations, 296t-297t
flexibility within, 287
high-risk individuals. See Special circumstances
modified/alternative schedules, 247, 259-260
safety of, 260
Schools
coverage surveys, 75
school-aged immunization platform, 302t
school immunization mandates, 111-113
school-located vaccination (SLV), 131-132
Screening for contraindications/precautions, 134, 138t-140t, 240t-241t
Section 317 funds, 83-86
Self/non-self recognition, 23, 24, 25
Serial passage, 11-16
Seroconversion, 31
testing for, 171
Serology, 167-171
Serotype replacement, 43, 45, 490
Sewage workers, 229t
Sharps use and precautions, 105, 110
Shingles. See Zoster (herpes zoster; shingles).
Shingrix (RZV; recombinant zoster vaccine), 12t, 35, 123t, 530-536, 532t-534t
Simian virus 40 (SV40), 270-271
Smallpox, 477-488
bioterrorism potential of, 46-47, 478
clinical features, 477-478
diagnosis of, 480t-481t
differentiating from chickenpox, 480t-481t
mortality rates, 46, 477
correlates of protection, 38t
epidemiology and transmission, 478
immunization program, 478-479
ring vaccination, 478-479
pathogen, 477, 569t
cross-protection through vaccinia virus, 479
elimization/eradication of, 46-47, 49t, 478
vaccines, 124t, 479-483, 482t
ACAM2000, 124t, 479, 482t, 483-484
administration and handling, 142, 483
characteristics and specifics of, 482t, 569t
compensation for injuries from pandemic/epidemic administration, 484
contraindications/precautions, 153, 210, 483-484, 486t-487t
Dryvax, 479
immunogenicity/efficacy, 483, 485
investigational vaccines (Aventis Pasteur and Imvamune), 479-483
post-event vaccination, 479, 484, 485
pre-event vaccination, 478-479
recommendations, 478-479, 484-485
for revaccination, 485
safety, 483-484
schedule, 482t
storage, 124t
Ticovirimat (antiviral smallpox treatment), 484
trade name (ACAM2000), 124t, 482t
vaccinia immune globulin intravenous, 484
Society of Teachers of Family Medicine, 556t
Somatic hypermutation, 25
Special circumstances, 183-232, 296t-297t
adults over 65 years of age, 215-216
coverage rates in special populations, 186-187, 192t-193t
health care personnel, 216-219
immune deficiency states, 187-204
impaired immunity, 183-185, 296t
B-cell (humoral) deficiencies, 191-198
cancer chemotherapy, 203-204
disease-modifying antirheumatic drugs (DMARDs), 200-201
hematopoietic stem cell transplantation, 204, 206t-209t
HIV infection, 187-191, 296t
solid organ transplantation, 201-204, 202
inborn errors of metabolism, 214-215
international adoptees, refugees, and immigrants, 220-221
Special circumstances, continued
miscellaneous special situations, 227, 228t-229t
newborns, 186, 211
other predisposing conditions, 186, 204-207
pregnancy, postpartum, and breastfeeding, 204-211, 212t-213t, 296t
preterm and low birth weight infants, 214
travel, 221-227
specificity of antibodies, 19, 27, 27
Spelunkers, 229t, 460t
Standards, principles, and regulations, 91-116. See also Vaccine infrastructure; Vaccine practice.
Bloodborne Pathogens Standard, 105-111
coverage goals, 91-92
Healthy People 2020, 91-92
immunization practices, standards, 92-97
adult, 95-97, 98t-99t
child and adolescent, 92-95
mandates and exemptions, 111-114
National Childhood Vaccine Injury Act, 77, 97-101
National Vaccine Injury Compensation Program (VICP), 97-101
Occupational Safety and Health Administration (OSHA), 105-111
Public Readiness and Emergency Preparedness Act, 101
Reportable Events Table, 97, 106t-109t
reporting of adverse events, 77-79
training, 111
Vaccine Adverse Event Reporting System (VAERS), 77-79, 101
Vaccine Information Statements (VISs), 101, 102t-104t
Standing orders, 132, 145, 369
Steroids, 200
Stockpiles of vaccines, 62, 87, 401, 483
Storage of vaccines, 119-128, 120t-125t. See also specific vaccines.
eMERGENCY provisions for, 127t
in freezer, 119-126, 123t-124t
in refrigerator, 119-126, 120t-123t
temperature monitoring and logs, 119-126
Streptococcus pneumoniae, 255, 489-497, 569t. See also Pneumococcal vaccines; Pneumonia.
impaired immunity and, 186
optimizing immunity to, 188-190
serotypes and herd immunity, 43, 44, 45
Students. See College students.
Subcutaneous administration of vaccines, 141, 142
Subunits
engineered, 12t, 17-18
purified, 12t, 17
recombinant, 12t, 17-18
Sudden infant death syndrome (SIDS), 271-272
Supply of vaccines, 86-87
Surrogates of immunity. See Correlates of protection.
Surveillance, 76. See also Vaccine Safety Net.
special surveillance efforts, 80-81
SV-40 contamination of early polio vaccine, 270-271
Swine flu, 80, 81
Synagis (palivizumab), 19, 166, 168t
Syncpe, 106t-109t, 145-146
Systems immunology, 18
T cells, 27
cytotoxic (Tc cells), 25, 32-36, 34
activation of, 32, 34
deficiencies of, 184, 198
helper (Th-cells), 22, 24-25, 32
memory Th-cells, 27
memory T-cells, 26, 27
T-cell-dependent responses, 32, 35
T-cell-independent antigens and responses, 23, 32
T-cell receptor (TCR), 22, 24, 32, 34
Table injury, 99
Task Force on Safer Childhood Vaccines, 81
Td (tetanus, diphtheria) vaccine, 334t-335t, 337
contraindication and precautions, 336-337
minimum ages and intervals for, 159t
recommendations, 337-338
for wound management, 340t-341t
schedule, 335t, 337
adults, by age, 298
adults, by medical condition/indication, 300
catch-up, children age 7-18 years, 294
trade names
Tenivac, 334t-335t
Tetanus and Diphtheria Toxoids Adsorbed, 334t-335t
Tdap vaccines, 330t-332t. See also Diphtheria, tetanus, and pertussis; DTaP vaccines.
administration errors and remedies, 176t
contraindications/precautions, 336
Guillain-Barré syndrome, 336
immunogenicity/efficacy, 328
licensure of, 40
minimum ages and intervals, 159t, 290
recommendations, 65t, 255, 326-328, 327, 331t, 337-338
health care personnel, 219, 327
pregnancy, 205, 212t, 327, 328, 338
for wound management, 340t-341t
safety, 336
schedule, 331t
adults, by age, 298
adults, by medical condition/indication, 300
catch-up, children age 7-18 years, 294
children, age 7-18 years, 290
Tdap vaccines, continued
storage, 123t
trade names (Adacel, Boostrix), 330t-332t
vs DTap, 164
Temperature for vaccine storage, 119-126
Tenvac (Td), 123t, 334t-335t. See also Td (tetanus, diphtheria).
Terminology, vi-vii, 568t-569t
indication, recommendation, requirement, 68t-69t
language and meaning, 245t
Terrorism. See Bioterrorism.
Tetanus, 323-341. See also Diphtheria, tetanus, and pertussis.
clinical features, 324
correlates of protection, 39t
epidemiology and transmission, 325
immune globulin (TIG), 169t, 324, 328, 340t
immunization program, 326
neonatal tetanus, 324, 325
pathogen, 323, 325, 568t
vaccines, 12t, 328, 330t-332t, 334t-335t. See also DT; DTap; Td; Tdap; Tetanus toxoid (TT).
characteristics and specifics of, 330t-332t, 334t-335t, 568t
combination vaccines, 538-539, 540t-546t
contraindications/precautions, 333-337
immunogenicity/efficacy, 328-333
recommendations, 326-328, 327, 337-338
adult. See Tdap vaccines.
children/infants. See DTap vaccines.
for wound management, 340t-341t
safety, 333-337
reportable events, 106t
schedule, 331t, 334t, 337-338
storage, 123t
trade names, 330t, 334t
Adacel (Tdap), 330t-332t
Boostrix (Tdap), 330t-332t
Daptacel (DTaP), 330t-332t
Diphtheria and Tetanus Toxoids Adsorbed (DT), 334t-335t
Infanrix (DTaP), 330t-332t
Tenvac (Td), 334t-335t
Tetanus and Diphtheria Toxoids Adsorbed (Td), 334t-335t
Tetanus and Diphtheria Toxoids Adsorbed (Td), 334t-335t
Tetanus immune globulin (TIG), 169t, 324, 328
anaphylactic reaction to, 337
interval for live vaccines and, 169t
precautions, 337
for wound management, 340t-341t
Tetanus toxoid (TT), 12t
Tetanus Toxoids Adsorbed (DT, Td), 334t-335t
contraindications/precautions, 336-337
Texas Children’s Hospital Center for Vaccine Awareness and Research, 556t
Th-cells (helper T lymphocytes), 22, 24-25, 32
differentiation of, 25
direct antimicrobial functions, 25
memory Th-cells, 26, 27
Thimerosal, 254, 264-266. See also specific vaccines.
Thrombocytopenia, 237, 275, 425
Ticovirimat (antiviral smallpox treatment), 484
TIG. See Tetanus immune globulin.
Timeline of vaccine development, 51
Timeliness of vaccine delivery, 73, 538
Tofacitinib, 201
Toll-like receptors (TLRs), 24
Topical anesthetics, 145
Toxins, 31, 32, 467
antibodies to, 19, 40
cholera toxin, 317, 318
Toxoid vaccines, 12t, 17, 334t-335t, 338, 340t-341t
Toxoids, 17
Tracking systems, 128-129
Transplantation
hematopoietic stem cell (HSCT), 204, 206t-209t
solid organ, 192t, 201-204, 202
Transportation of vaccines, 126-128
Travel, 221-227
disease transmission due to, 255
diseases related to, 226-227
cholera, 227, 317
invasive meningococcal disease, 226
Japanese encephalitis, 226, 415
measles, 221
rabies, 226
typhoid fever, 221, 226, 500
yellow fever, 227, 520
proof of vaccination, 222, 227, 525
travel medicine clinics, 222
vaccination for, 221-227
cholera, 227, 321
hepatitis A (or IGIM), 222-223, 350, 355
hepatitis B, 222-223, 370
influenza, 221
Japanese encephalitis, 415
mandatory vaccines, 227
measles, 221
meningococcal vaccine (Saudi Arabia/Hajj), 227
N meningitidis, 195, 226, 443
polio, 223-226, 449
rabies, 226, 460t
routine vaccines, being up-to-date, 222
typhoid fever, 505
Travel, continued

Web sites on, 227
yellow fever, 227, 524-525
Trumenba (MenB-FHbp), 175t, 435, 436t-439t
immunogenicity, 441
minimum ages and intervals, 158t
recommendations, 64t, 433, 435
storage, 122t
Tsar/Tsarina (for immunization), 117, 118t, 134
TT. See Tetanus toxoid (TT).
Tuberculin skin test (TST), 425, 484, 513, 524
Tuberculosis, 16
TViPSV. See Typhim Vi.
Twinrix (HepA-HepB), 121t, 538, 548t-551t
Ty21a. See Vivotif.
Typhim Vi (TViPSV), 123t, 501-505, 502t-503t
Typhoid fever, 499-506
clinical features, 499-500
epidemiology and transmission, 500
immunization program, 500
pathogen, 499, 569t
vaccines, 501, 502t-503t, 569t
contraindications/precautions, 191, 504
immunogenicity/efficacy, 501
recommendations, 500, 505
for travel, 226, 505
safety, 504
schedule, 503t
storage, 123t
TViPSV (Typhim Vi), 123t, 501-505, 502t-503t
Ty21a (Vivotif), 16, 501-505, 502t-503t

Universal precautions, 110
Vaccinate Your Family, 556t
Vaccination. See also Immunization; Vaccinology.
basic concepts, 11-52
as civic duty, 247
coverage goals, 91-92
cytotoxic T cells, implications for, 32-35
defined, 11
general recommendations, 153-181
germinal center reaction, implications for, 26-32
goals, 46-48
public health impact of, 46-50, 49t, 52t
sources of information on, 240-241, 242
triumphs of, 49t
Vaccination programs. See specific diseases.

Vaccine(s). See also Immunization; specific vaccines.
abbreviations, 559t-560t
basic immunology of, 19-36
classification of, 12t-13t
concerns about, 233-285
correlates of protection, 36-40, 38t-39t
costs/cost-benefit analyses. See Costs.
delivery of. See Delivery of vaccines.
development of. See Vaccine development and licensure.
documentation of vaccinations received, 128
effectiveness, vs efficacy, 36, 58
funding for. See Financing.
how they work, 19-36
impact of, 48-50, 49t, 52t
inactivated, 12t, 14t, 17-18
interchangeability of vaccines from different manufacturers, 164
licensure of. See Vaccine development and licensure.
live vaccines, 11-16, 12t-13t, 21
live vs inactivated vaccines, 14t-15t, 35
National Vaccine Plan, 71, 97
necessity of, 254-255
nomenclature, vi-vii, 568t-569t
number of, and timeline of development, 50, 51
prices of. See Costs.
recommendations regarding, See Recommendations.
resources on, 554t-558t
schedules for. See Schedules for immunization.
stockpiles of, 62, 87, 401, 483
supply/shortages, 86-87
timeline of development for specific diseases, 51
valency, vii
virus stocks, destruction of, 46-47
Vaccine acceptance, hesitancy, and confidence, 233, 234t
Vaccine Adverse Event Reporting System (VAERS), 77-79, 101
limitations of, 78
mandatory reporting to, 77, 94, 101, 103t
Vaccine confidence, 233, 234t, 244
Vaccine development and licensure, 53-62, 54
agencies involved with, 54, 66, 78
animal models, 53
Biologics License Application (BLA), 58-59
“breakthrough therapy” category, 59
clinical trials, 55-58, 56
costs of, 53
emergency preparedness, 62
FDA and, 53-55, 54
financial risk involved, 53
financing for, 81-86
noninferiority standard, 56, 538
Vaccine development and licensure, continued
package insert (PI), 59-62
postmarketing activities, 58, 76
prelicensure trials, 55-58, 56
steps in, 53-59, 54, 56
timeline for specific vaccines, 51
VRBPAC and, 59, 66
Vaccine failure, 31, 58, 60t-61t
causes of, 60t-61t
Vaccine immunology, 19-36. See also Immune response.
Vaccine Information Statements (VISs), 101, 102t-104t, 239
Vaccine infrastructure in the U.S., 53-90, 54
Defense Medical Surveillance System, 80
disease surveillance, 76
emergency preparedness, 62, 101, 145-146
financing, 81-86
governmental agencies, 54, 66, 554t
monitoring delivery, 73-75
monitoring safety, 76-81
policy and recommendations, 62-72
supply, 86-87
vaccine development and licensure, 53-62, 54, 78
Vaccine Injury compensation Program (VICP), 66, 97-101.
See also Vaccine Adverse Event Reporting System (VAERS).
children in utero covered by, 211
compensation under, 100
proof of causation, 99
Reportable Events Table, 106t-109t
Table injury, 99
vaccines covered, 100, 103t (footnote e)
Vaccine Injury Table (VIT), 97, 106t-109t
Table injury, 99
Vaccine policy and recommendations, 62-72. See also Recommendations.
agencies involved with, 66
terms used in reference to, 68t-69t
Vaccine practice, 117-152. See also Administration of vaccines.
administration of vaccines, 135-150
coding, billing, and costs, 146-150
delivery of vaccines, improving, 128-134
emergencies, 127t, 145-146
general guidelines, 117-128
handling, storage, and transport, 117-128
inventory, 117-118
signs, 117, 119, 126
storage, 119-128, 120t-125t
transport, 126-128
Immunization Tsar/Tsarina, 117, 118t, 134
screening for contraindications, 134, 138t-140t
standards for, 92-97
Vaccine-preventable diseases, 51, 67. See also Public health.
annual deaths from, 95, 392, 393-394, 394
costs of, 95
immunization goals, 91-92
necessity of vaccination for, 254-255
resurgence of, 48, 249-254, 326, 421-424
surveillance, 76
timeline of specific vaccine development, 51
Vaccine purchasing group (VPG), 147
Vaccine recommendations. See Recommendations.
Vaccine refusal, 246-248, 246
Vaccine Safety DataLink (VSD), 79, 145, 205
Vaccine Safety Net, 76-81, 78
ad-hoc committees and task forces, 81
Brighton Collaboration, 80
Clinical Immunization Safety Assessment (CISA) Network, 79-80, 555t
Defense Medical Surveillance System, 80
IOM Consensus Report, 81
Post-licensure Rapid Immunization Safety Monitoring (PRISM), 79
special surveillance efforts, 80-81
Vaccine Adverse Event Reporting System (VAERS), 77-79, 101
Vaccine Safety DataLink, 79
Vaccines and Related Biological Products Advisory Committee (VRBPAC), 59, 66
Vaccines for Children (VFC) Program, 63, 82-83, 118
common questions about, 84t-85t
Vaccines.gov, 556t
Vaccinia immune globulin, 484
Vaccinia virus, 479. See also Smallpox.
Vaccinology, 11-52. See also Immunization.
basic vaccine immunology, 19-36
classical vs reverse, 18
correlates of protection, 36-40, 38t-39t
genetics of vaccine responses/adverse events, 43-46
herd immunity, 40-43, 41
immunization, 11-19
public health and vaccines, 46-50, 49t
systems immunology, 18
Vaccinomics, 46
VAERS. See Vaccine Adverse Event Reporting System.
Value of Vaccination, 556t
Vaqta (HepA), 120t, 351, 352t-354t
Varicella, 507-517
chickenpox, 35, 164, 165, 255, 480t, 507
clinical features, 507-508, 511
breakthrough/vaccine-modified varicella, 507-508
congenital varicella syndrome, 508
diagnosis, 480t-481t
differentiating from smallpox, 480t-481t
Varicella, continued

- progressive and hemorrhagic varicella, 508
- societal burden of, 70, 509
- correlates of protection, 39t
- evidence of immunity, 515t
- epidemiology and transmission, 508
- herpes zoster (shingles) and. See Zoster.
- immune globulin (VariZIG), 169t, 509, 513, 514-516
- immunization program, 509, 511
  - cost effectiveness of, 509
  - one-dose program, 48, 509
  - two-dose program, 509
- pathogen (varicella-zoster virus, VZV), 507, 569t
  - attenuation of, 11-16
  - latency and, 507, 512, 527
  - reactivation of latent, 35, 507, 508, 512, 527, 528
- vaccines (VAR), 509-514, 510t-511t. See also MMRV; Zoster
  - administration errors and remedies, 176t
  - contraindications/precautions, 512-513
  - evidence of immunity, 515t
  - immunogenicity/efficacy, 509-512
  - interval for receipt of antibody-containing products, 165-166, 168t-170t
  - minimum ages and intervals, 153, 159t, 290
- primary vaccine failure, 509
- recommendations, 509, 514-516
  - considerations in, 70
  - health care personnel, 219, 509
  - HIV-infected children, 187-191
  - MMR plus VAR, preferred over MMRV, 420, 538, 539
  - pregnant women and, 514-516
- safety, 512-513
  - reportable events, 108t
- schedule, 510t, 514
  - adults, by age, 298
  - adults, by medical condition, 300
  - children, age 0-18 years, 290
  - catch-up, children age 4 months-6 years, 293
  - catch-up, children age 7-18 years, 294
- serial passage, 11-16
- storage and transport, 124t, 126
- trade name (Varivax), 124t, 510t-511t
- vs zoster vaccines (ZVL), 35
- VariZIG (varicella zoster immune globulin), 169t, 509, 513, 514-516
- waning immunity and, 508, 527

Varicella-zoster immune globulin. See VariZIG.

Varicella-zoster virus (VZV), reactivation of latent, 35, 507, 508, 512, 527, 528. See also Zoster (herpes zoster; shingles).

Variola, 477-478, 569t. See also Smallpox.
- last remaining stocks of, 46-47, 478
- terrorism potential of, 46-47, 478
- variola major, minor, and sine erupitio, 478-479
- Varivax (varicella vaccine), 124t, 509-514, 510t-511t. See also Varicella, vaccines.
- VariZIG (varicella zoster immune globulin), 18, 169t, 509, 514-516. See also Varicella.
  - for health care personnel, 219
  - IgA deficiency and, 513
  - interval for live vaccines and, 169t
  - for pregnant women, 211, 514-516
  - safety, 513
- Vaxchora (cholera vaccine), 123t, 227, 319, 320t
- Vaxelis (DTaP-HepB-IPV-Hib-OMP), 120t, 540t-546t
- VFC. See Vaccines for Children (VFC) Program.
- Vibrio cholerae, 16, 317, 568t
- VICP. See Vaccine Injury Compensation Program.
- Viral infections, 35
- Viral interference, 537
- Viruses, vs bacteria, 32-35
- Vivotif (Ty21a), 16, 123t, 501-505, 502t-503t
- Voices for Vaccines, 556t
- VRBPAC (Vaccines and Related Biological Products Advisory Committee), 59, 66
- VZV (varicella-zoster virus), 507. See also Varicella
  - Waning immunity, 48, 255, 329, 509, 527
  - Warning labels, 110
  - Whole agent vaccines, 12t, 17
  - Whooping cough. See Pertussis.
  - Woolsorter’s disease, 309
  - World Health Organization (WHO), 554t

X-linked agammaglobulinemia (XLA), 184

Yellow fever, 519-526
- clinical features, 519
- epidemiology and transmission, 520
- immunization program, 520
- International Certificate of Vaccination or Prophylaxis, 227, 525
- pathogen, 519, 569t
- vaccine for (YFV), 12t, 123t, 501-505, 502t-503t
- adverse events, serious, 521-523
  - approved sites for administration, 227, 525
  - contraindications/precautions, 211, 523-524
  - immunogenicity/efficacy, 521
  - recommendations, 154, 524-525
  - for pregnant women, 211, 524, 525
  - travel, 227, 524-525
Yellow fever, continued
  safety, 273, 521-524
  vaccine-associated neurotropic disease, 523, 525
  vaccine-associated viscerotropic disease, 521-523
  schedule, 522t
  storage, 123t
YF-Vax (yellow fever vaccine), 12t, 123t, 521-525, 522t-523t

Zostavax (ZVL, zoster vaccine live), 65t, 530-536, 532t-534t
  storage, 124t
Zoster (herpes zoster; shingles), 527-536. See also Varicella.
  clinical features, 527-528
  age and, 528
  zoster sine herpete, 528
  correlates of protection, 39t
  epidemiology and transmission, 528-529
  reactivation of latent VZV, 35, 507, 508, 512, 527, 528
  risk factors and incidence, 528-529
  varicella vaccination, protection provided by, 529
herpes zoster (shingles), 35, 256, 507-508, 527
  immunization program, 529-530
  cost-effectiveness of, 529-530
pathogen, 527, 569t
postherpetic neuralgia (PHN) and, 256, 527, 528
  vaccines for (ZVL, RZV), 12t, 530-536, 532t-534t
  administration errors and remedies, 175t, 176t
  contraindications/precautions, 531-535
  immunogenicity/efficacy, 530-531
  live-attenuated (ZVL), 12t, 35, 65t, 530-536, 532t-534t
  minimum ages and intervals, 159t, 166
  recombinant (RZV), 12t, 35, 123t, 530-536, 532t-534t
  recommendations, 65t, 216, 530, 535-536
  safety, 531-535
  schedule, 533t
  adults, by age, 298, 535
  adults, by medical condition/indication, 300
  storage, 123t, 124t
  trade names (Zostavax; Shingrix), 532t
  vs varicella vaccine (VAR), 35
varicella exposure and, 529
ZVL (zoster vaccine live). See under Zoster.